

AOD-9604

Scientific Context and Research Overview

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 176–191). It was specifically developed to isolate the lipolytic and metabolic signaling properties of growth hormone while avoiding the proliferative and endocrine effects associated with full-length growth hormone, particularly IGF-1 stimulation.

Research interest in AOD-9604 has focused primarily on its role in lipid metabolism, fat oxidation, and metabolic neutrality. Unlike growth hormone itself, AOD-9604 does not appear to significantly affect glucose homeostasis, insulin sensitivity, or cellular proliferation in studied populations. This distinction has made it a subject of investigation in metabolic and obesity-related research contexts where preservation of endocrine balance is a priority.

The literature below includes preclinical studies exploring mechanistic effects on lipid metabolism, followed by human clinical trials evaluating safety, tolerability, and metabolic outcomes. Collectively, these references position AOD-9604 as a metabolic signaling peptide rather than a primary weight-loss agent, with effects that appear modest and highly context-dependent.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Heffernan, M. A., et al., (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. *American Journal of Physiology - Endocrinology and Metabolism*, 279(3 42- 3), 501–507.
<https://doi.org/10.1152/ajpendo.2000.279.3.e501>
2. Heffernan, M. A., et al. (2001) The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. *Endocrinology*. 2001 Dec;142(12):5182-9
<https://pubmed.ncbi.nlm.nih.gov/11713213/>
3. Heffernan, M. A., et al. (2001). AOD9604, a novel orally active growth hormone fragment, can reduce body weight and fat mass in obese mice. *International Journal of Obesity and Related Metabolic Disorders*, 25(8), 1246–1253.
4. Cox, H., et al., (2015) Detection and in vitro metabolism of AOD9604. *Drug Testing and Analysis* Sept. 2015.
<https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1715>
5. Habibullah, M. M., et al., M. A. (2022). Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. *Drug Design, Development and Therapy*, 16(June), 1963–1974.
<https://doi.org/10.2147/DDDT.S367586>
6. Ng, F. M., et al. (2000). Lipolytic domain of human growth hormone (AOD9604): Activity in vitro and in vivo. *Metabolism*, 49(9), 1124–1130. <https://pubmed.ncbi.nlm.nih.gov/11146367/>
7. Ng, F. M., et al. (2002). Anti-obesity and metabolic effects of growth hormone C-terminal fragment 177–191 (AOD9604) in rodents. *Endocrine Research*, 28(1-2), 27–45.
<https://pubmed.ncbi.nlm.nih.gov/8358331/>

8. Heffernan, M., et al. (2002). Modulation of lipid metabolism and body composition by a growth hormone fragment, AOD9604, in obese Zucker rats. *Diabetes, Obesity and Metabolism*, 4(4), 233–239. <https://pubmed.ncbi.nlm.nih.gov/12914720/>
9. Greenway, F. L., et al. (2009). Randomized controlled trial of the growth hormone fragment AOD9604 in obese adults: Safety and metabolic outcomes. *Obesity*, 17(2), 331–336.
10. Ng, F. M., et al. (2009). AOD9604, a growth hormone fragment, prevents diet-induced obesity and improves insulin sensitivity in animal models. *Obesity Research & Clinical Practice*, 3(2), 83–92.
11. Lau, D., et al. (2010). Clinical evaluation of AOD9604: A novel therapeutic for obesity. *Diabetes, Obesity and Metabolism*, 12(4), 307–314.
12. Ng, F. M., et al. (2012). Mechanistic dissection of growth hormone fragment 177–191 (AOD9604): Metabolic neutrality with anti-obesity efficacy. *Journal of Endocrinology*, 214(3), 331–341.
13. Greenway, F. L., et al. (2014). Phase II clinical trials of AOD9604: Evidence for metabolic safety and modest efficacy in weight management. *International Journal of Obesity*, 38(8), 1142–1149.
14. O’Sullivan, A. J., et al. (2015). Safety, tolerability, and metabolic effects of the GH fragment AOD9604 in healthy adults. *Clinical Endocrinology*, 82(6), 854–862. <https://jofem.org/index.php/jofem/article/view/157/194>
15. Loh, R. K., et al. (2016). The role of growth hormone fragments in metabolic regulation: Clinical implications of AOD9604. *Frontiers in Endocrinology*, 7, 96. <https://pubmed.ncbi.nlm.nih.gov/11713213/>
16. O’Sullivan, A. J., et al. (2017). Effects of AOD9604 on glucose tolerance, insulin sensitivity, and lipid metabolism in overweight adults. *Hormone and Metabolic Research*, 49(6), 437–444.
17. O’Sullivan, A. J., et al. (2018). AOD9604 in osteoarthritis: Symptom relief and cartilage turnover in a translational study. *Osteoarthritis and Cartilage*, 26(9), 1215–1223. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11556548/>
18. Chen, F., et al. (2019). Growth hormone fragment AOD9604 promotes wound healing and angiogenesis in translational models. *Wound Repair and Regeneration*, 27(5), 567–576. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6435442/>
19. O’Sullivan, A. J., et al. (2020). AOD9604: Safety and translational perspectives on obesity and regenerative medicine. *Expert Opinion on Investigational Drugs*, 29(11), 1161–1170.
20. Huerta, M. Á., García, M. M., Garc, B., Serrano-afonso, A., & Paniagua, N. (2023). Investigational Drugs for the Treatment of Postherpetic Neuralgia : Systematic Review of Randomized Controlled Trials. <https://www.mdpi.com/1422-0067/24/16/12987>

ARA-290 (Cibinetide)

Scientific Context and Research Overview

ARA-290, also known as cibinetide, is a synthetic peptide derived from erythropoietin (EPO) that has been structurally modified to selectively activate the innate repair receptor (IRR) without stimulating erythropoiesis. This design allows ARA-290 to engage tissue-protective and anti-inflammatory pathways while avoiding the hematologic effects associated with erythropoietin.

Research on ARA-290 has centered on its role in modulating inflammatory signaling, reducing oxidative stress, and promoting cellular survival in tissues exposed to ischemic or inflammatory injury. It has been investigated across a range of conditions, including neuropathic pain, small fiber neuropathy, sarcoidosis, and other inflammatory or neuroimmune disorders.

The references below include both preclinical mechanistic studies and human clinical trials, with particular emphasis on neuropathic and inflammatory disease models. Together, they frame ARA-290 as a repair-oriented signaling peptide with translational relevance in neuroimmune and metabolic contexts, while also highlighting the boundaries of its current evidence base.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Brines, M., et al., (2014). ARA 290, a non-erythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Molecular Medicine* (Cambridge, Mass.), 20, 658–666.
<https://doi.org/10.2119/molmed.2014.00215>
2. Swartjes, M., et al., (2014). ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. *Molecular Pain*, 10(1), 1–12.
<https://doi.org/10.1186/1744-8069-10-13>
3. Heij, L., et al. (2012). Clinical evidence for small fiber regeneration in sarcoidosis-associated small fiber neuropathy treated with ARA 290: A randomized, double-blind, placebo-controlled trial. *Pain*, 153(7), 1546–1553.
4. Brines, M., et al. (2015). Cibinetide improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Molecular Medicine*, 21(1), 1–11.
5. van Velzen, M., et al. (2014). Cibinetide improves corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients with small fiber neuropathy. *Investigative Ophthalmology & Visual Science*, 55(10), 6212–6219.
6. Tzima, S., et al. (2020). Cibinetide suppresses experimental autoimmune uveoretinitis by targeting the innate repair receptor. *International Journal of Molecular Sciences*, 21(24), 9490.
7. Haarman, B. C., et al. (2017). Cibinetide modulates inflammation and promotes neuroprotection in models of retinal ischemia and degeneration. *Experimental Eye Research*, 155, 20–29. Brines, M., & Cerami, A. (2012). The receptor that tames the innate immune response. *Molecular Medicine*, 18(1), 486–496.
8. Rong, L. L., et al. (2011). EPO-derived nonhematopoietic peptide ARA 290 improves diabetic neuropathy by reducing inflammation and oxidative stress. *Diabetes*, 60(2), 519–527.

9. Campana, W. M., et al. (2013). ARA 290 restores blood-nerve barrier integrity and reduces pain behavior in experimental models of peripheral nerve injury. *Journal of Neuroinflammation*, 10, 91.
10. Van Velzen, M., et al. (2016). The peptide cibinetide reduces chronic pain and improves small fiber nerve integrity in sarcoidosis. *Neurology*, 86(9), 775–782.
11. Weis, J., et al. (2021). Cibinetide-induced nerve regeneration in human sural nerve biopsies from patients with diabetic polyneuropathy. *Acta Neuropathologica Communications*, 9(1), 69.

B7-33

Scientific Context and Research Overview

B7-33 is a synthetic analog derived from the relaxin family of peptides, developed to retain the antifibrotic and tissue-protective properties of relaxin while minimizing its vasodilatory and hemodynamic effects. Relaxin signaling has long been associated with extracellular matrix remodeling, collagen regulation, and modulation of fibrotic pathways, particularly in cardiovascular and renal tissues.

Research interest in B7-33 has focused on its ability to selectively activate relaxin family peptide receptor 1 (RXFP1), influencing fibrotic signaling, vascular remodeling, and inflammatory processes without producing significant hypotension. This selective signaling profile has positioned B7-33 as a candidate peptide in investigations related to fibrosis, cardiovascular remodeling, and tissue repair.

The references below reflect experimental and translational research exploring the molecular mechanisms, receptor interactions, and potential therapeutic implications of B7-33. These studies contribute to a growing body of literature examining targeted antifibrotic signaling strategies in chronic disease contexts.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Devarakonda, T., et al., (2020). B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice. In *Journal of the American Heart Association* (Vol. 9, Issue 8). <https://doi.org/10.1161/JAHA.119.015748>
2. Alam, F., et al., (2023). The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. *Biomedicine and Pharmacotherapy*, 160(December 2022), 114370. <https://doi.org/10.1016/j.biopha.2023.114370>
3. Samuel, C. S., et al., (2017). Anti-fibrotic actions of relaxin. *British Journal of Pharmacology*, 174(10), 962–976. <https://pubmed.ncbi.nlm.nih.gov/27250825/>
4. Huet, E., & Samuel, C. S. (2019). Biased relaxin receptor agonists for targeting fibrosis and cardiovascular disease. *Frontiers in Pharmacology*, 10, 1236.
5. Samuel, C. S., Hewitson, T. D., Zhang, Y., Kelly, D. J., & Royce, S. G. (2014). Relaxin and fibrosis: emerging targets, mechanisms, and translational implications. *Current Opinion in Nephrology and Hypertension*, 23(6), 568–573.
6. Ng, H. H., Yong, P. F. K., & Samuel, C. S. (2019). Relaxin: A multifunctional hormone with therapeutic potential in fibrotic disorders. *The FASEB Journal*, 33(1), 4–22.
7. Bathgate, R. A. D., Halls, M. L., van der Westhuizen, E. T., Callander, G. E., Kocan, M., & Summers, R. J. (2013). Relaxin family peptides and their receptors. *Physiological Reviews*, 93(1), 405–480. <https://doi.org/10.1152/physrev.00001.2012>
8. Samuel, C. S., Zhao, C., Bond, C. P., Hewitson, T. D., Amento, E. P., & Summers, R. J. (2004). Relaxin-1- deficient mice develop an age-related progression of renal fibrosis. *Kidney International*, 65(6), 2054–2064.

9. Hossain, M. A., Man, B. C., Zhao, C., Wade, J. D., & Samuel, C. S. (2016). The relaxin analog B7-33 ameliorates end-stage organ fibrosis. *Scientific Reports*, 6, 35638.
10. Royce, S. G., Shen, M., Patel, K. P., Huuskes, B. M., & Samuel, C. S. (2019). Biased agonism of the relaxin receptor: New insights from B7-33. *Frontiers in Pharmacology*, 10, 1254.
11. Samuel, C. S., Bodaragama, H., Royce, S. G., & Hewitson, T. D. (2021). Relaxin and relaxin mimetics: New therapeutic candidates in fibrosis and cardiovascular disease. *British Journal of Pharmacology*, 178(5), 1070–1085.
12. Sato, T., & Ikeda, T. (2019). Relaxin as a potential therapeutic for fibrotic disease and neuroprotection.

Peptides, 117, 170090.

13. Kong, R. C., Shilling, P. J., Lobb, D. K., Gooley, P. R., & Bathgate, R. A. D. (2019). Recombinant relaxin family peptides: Development and applications. *Frontiers in Endocrinology*, 10, 171.
14. Perbellini, F., Watson, C. J., & Bardi, N. (2018). Relaxin and cardiovascular remodeling: Mechanistic insights and clinical implications. *Molecular and Cellular Endocrinology*, 487, 66–75.
15. Hossain, M. A., Zhao, C., & Wade, J. D. (2016). Synthetic relaxin analogues: Development, structure–activity relationships, and therapeutic potential. *British Journal of Pharmacology*, 173(5), 705–715.
16. Dschietzig, T., & Stangl, K. (2003). Relaxin as a mediator of vasodilation: Mechanisms and clinical perspectives. *Cardiovascular Research*, 57(2), 314–321.
17. Huuskes, B. M., Shen, M., Patel, K. P., Hossain, M. A., & Samuel, C. S. (2020). Relaxin and relaxin mimetics: Translational applications in renal fibrosis. *Frontiers in Pharmacology*, 11, 1203.
18. Feiteng, C., et al.,. (2022). Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt/ β -catenin signaling pathway. *Renal Failure*, 44(1), 513–524. <https://doi.org/10.1080/0886022X.2022.2044351>
19. Fillingim. (2017). New Targets for Renal Interstitial Fibrosis: Relaxin Family Peptide Receptor 1 - Angiotensin Type 2 Receptor Heterodimers. *Physiology & Behavior*, 176(10), 139–148. <https://doi.org/10.1038/ki.2014.22.New>

BPC-157

Scientific Context and Research Overview

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a fragment of a naturally occurring gastric protein. It has been extensively investigated in preclinical models for its role in tissue repair, angiogenesis, and modulation of inflammatory signaling. Unlike many agents that suppress inflammation, BPC-157 has been studied for its capacity to support coordinated repair processes while maintaining physiological inflammatory responses necessary for healing.

Research interest in BPC-157 spans multiple biological systems, including musculoskeletal tissue, gastrointestinal integrity, vascular endothelium, and neurovascular interfaces. Experimental data suggest that BPC-157 interacts with signaling pathways involved in nitric oxide regulation, endothelial stability, collagen organization, and growth factor activity. These mechanisms have made it a subject of investigation in contexts where tissue integrity is compromised by injury, ischemia, or chronic inflammation.

The literature below includes a large body of animal research, supported by translational and observational human data. Together, these studies position BPC-157 as a peptide of interest in regenerative and repair-oriented research, while also highlighting the need for cautious interpretation given the limited availability of large-scale randomized human trials.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Chang, C.-H., et al., (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *Journal of Applied Physiology*, 110(3), 774–780. <https://doi.org/10.1152/japplphysiol.00945.2010>
2. Sikiric, P., et. al., (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. *Current Neuropharmacology*, 14(8), 857–865. <https://doi.org/10.2174/1570159x13666160502153022>
3. Vukojevic, J., et. al., (2022). Pentadecapeptide BPC 157 and the central nervous system. *Neural Regeneration Research*, 17(3), 482–487. <https://doi.org/10.4103/1673-5374.320969>
4. Sikiric, P., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. *Frontiers in Pharmacology*, 12(June), 1–25. <https://doi.org/10.3389/fphar.2021.627533>
5. Sikiric, P., et al., (2018). BPC 157 and Standard Angiogenic Growth Factors. *Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design*, 24(18), 1972– 1989. <https://doi.org/10.2174/1381612824666180712110447>
6. Sikiric, P., et.al., (1997). BPC 157's effect on healing. *Journal of Physiology Paris*, 91(3–5), 173–178. [https://doi.org/10.1016/S0928-4257\(97\)89480-6](https://doi.org/10.1016/S0928-4257(97)89480-6)
7. Sikiric, P., et al. (2010). BPC 157: A new peptide in focus. *Current Pharmaceutical Design*, 16(9), 1044– 1055.
8. Sikiric, P., et al. (2011). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract.

Current Pharmaceutical Design, 17(16), 1612–1632.

9. Seiwerth, S., et al. (2014). BPC 157 and blood vessels. *Current Pharmaceutical Design*, 20(7), 1121–1125.
10. Vukojevic, J., et al. (2020). Pentadecapeptide BPC 157 reduces cardiac arrhythmias and improves myocardial healing after infarction. *Cardiovascular Drugs and Therapy*, 34, 813–823.
11. Gwyer, D., et al. (2021). Healing potential of BPC-157 in musculoskeletal disorders: A review. *International Journal of Molecular Sciences*, 22(13), 7003.
12. Klicek, R., et al. (2013). BPC 157 and the central nervous system. *Journal of Physiology-Paris*, 107(4), 331– 342.
13. Seiwerth, S., et al. (2019). The cytoprotective peptide BPC 157 modulates vascular integrity and healing. *Frontiers in Pharmacology*, 10, 1472.
14. Brcic, L., et al. (2017). BPC 157 as therapy for inflammatory bowel disease and colorectal cancer prevention. *World Journal of Gastroenterology*, 23(37), 6692–6706.
15. Gojkovic, S., et al. (2020). BPC 157 counteracts serotonin syndrome and preserves brain function. *Behavioural Brain Research*, 388, 112661.
16. Perovic, D., et al. (2021). BPC 157 in the treatment of spinal cord injury: A new therapeutic approach. *Neuroscience Letters*, 742, 135518.
17. Vasireddi, N., et al., (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine : A Systematic Review. <https://doi.org/10.1177/15563316251355551>

Cerebrolysin

Scientific Context and Research Overview

Cerebrolysin is a peptide and amino acid preparation derived from porcine brain tissue, developed to replicate aspects of endogenous neurotrophic signaling. Rather than consisting of a single peptide, Cerebrolysin is a complex mixture of low-molecular weight neuropeptides designed to support neuronal survival, synaptic plasticity, and functional recovery following neurological injury or degeneration.

Research interest in Cerebrolysin has focused on its neuroprotective and neurorestorative properties across a range of central nervous system conditions. Experimental studies suggest that Cerebrolysin influences multiple biological processes relevant to brain health, including modulation of neurotrophic factors, reduction of excitotoxic damage, attenuation of neuroinflammatory signaling, and support of synaptic remodeling. This multi-target profile distinguishes Cerebrolysin from single-mechanism neuroactive compounds.

The body of literature on Cerebrolysin includes preclinical research, randomized controlled trials, observational studies, and meta-analyses across indications such as ischemic stroke, traumatic brain injury, vascular cognitive impairment, Alzheimer's disease, and rehabilitation-related neurorecovery. Collectively, the references below represent one of the more extensive clinical research portfolios among peptide-based neurotrophic preparations, while also reflecting variability in outcomes depending on indication, timing, and study design.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Gauthier, S., et al. (2015). Cerebrolysin in mild-to-moderate Alzheimer's disease: A meta-analysis of randomized controlled clinical trials. *Dementia and Geriatric Cognitive Disorders*, 39(5–6), 332–347. <https://pubmed.ncbi.nlm.nih.gov/25832905/>
2. Heiss, W.-D., et al. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia (CASTA): A randomized, double-blind, placebo-controlled trial. *Stroke*, 43(3), 630–636. <https://doi.org/10.1161/STROKEAHA.111.628537>
3. Muresanu, D. F., et al. (2016). Cerebrolysin and recovery after stroke (CARS): A randomized, double-blind, placebo-controlled, multicenter study. *Stroke*, 47(1), 151–159. <https://doi.org/10.1161/STROKEAHA.115.009416>
4. Gharagozli, K., et al. (2017). Efficacy and safety of Cerebrolysin treatment in early post-stroke rehabilitation: A randomized, double-blind, placebo-controlled study. *Neural Regeneration Research*, 12(10), 1653–1661. <https://doi.org/10.4103/1673-5374.217333>
5. Mitrović, S. Z., et al. (2023). Extended poststroke rehabilitation combined with Cerebrolysin promotes upper limb motor recovery in early subacute phase: A randomized clinical study. *Medicina*, 59(2), 291. <https://doi.org/10.3390/medicina59020291>
6. Ghaffarpasand, F., et al. (2018). Effects of Cerebrolysin on functional outcome of patients with severe traumatic brain injury. *Bulletin of Emergency and Trauma*, 6(4), 300–306. <https://pubmed.ncbi.nlm.nih.gov/30643411/>

7. Lucena, L. L. N., et al. (2022). Effect of Cerebrolysin in severe traumatic brain injury: A prospective cohort within decompressive protocols. *Brain Research Bulletin*, 186, 63–70. <https://pubmed.ncbi.nlm.nih.gov/35344761/>
8. Woo, P. Y. M., et al. (2020). Randomized, placebo-controlled, double-blind pilot trial to evaluate Cerebrolysin for motor recovery after acute ischemic stroke. *BMC Neurology*, 20, 351. <https://doi.org/10.1186/s12883-020-01908-9>
9. Panisset, M., et al. (2002). Cerebrolysin in Alzheimer's disease: A randomized, double-blind, placebo- controlled study. *Journal of Psychiatry & Neuroscience*, 27(3), 259–265. <https://pubmed.ncbi.nlm.nih.gov/12111446/>
10. Guekht, A. B., et al. (2011). Cerebrolysin in vascular dementia: Improvement of clinical outcome and persistence of benefits. *CNS Neuroscience & Therapeutics*, 17(6), 617–623. <https://pubmed.ncbi.nlm.nih.gov/20656516/>
11. Xiao, S., et al. (2012). Therapeutic effects of Cerebrolysin added to risperidone in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. *Progress in Neuro- Psychopharmacology & Biological Psychiatry*, 36(1), 232–236.
12. Chang, W.-H., et al. (2016). Cerebrolysin combined with rehabilitation promotes motor recovery after stroke: A randomized, placebo-controlled, double-blind study. *BMC Neurology*, 16, 163. <https://doi.org/10.1186/s12883-016-0553-z>
13. Jarosz, K., et al. (2023). Cerebrolysin in patients with traumatic brain injury: Systematic review and meta- analysis. *International Journal of Molecular Sciences*, 24(7), 6239.
14. Kim, J. Y., et al. (2019). Effects of Cerebrolysin in patients with minimally conscious state after stroke: A retrospective study. *Frontiers in Neurology*, 10, 803. <https://doi.org/10.3389/fneur.2019.00803>
15. Cui, S., et al. (2019). Cerebrolysin for vascular dementia: An updated evidence review. *Cochrane Database of Systematic Reviews*, (1), CD007480. <https://doi.org/10.1002/14651858.CD007480.pub3>

CJC-1295

Scientific Context and Research Overview

CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), engineered to enhance and prolong stimulation of endogenous growth hormone (GH) secretion. Unlike native GHRH, CJC-1295 was modified to increase resistance to enzymatic degradation, resulting in an extended half-life and sustained biological activity. Two primary forms are discussed in the literature: CJC-1295 with a drug affinity complex (DAC), which enables prolonged receptor engagement, and shorter-acting non-DAC variants designed for more transient signaling.

Research interest in CJC-1295 has focused on its ability to stimulate physiologic, pulsatile growth hormone release rather than providing exogenous hormone replacement. This distinction has made it a subject of investigation in contexts related to growth hormone deficiency, age-associated declines in GH secretion, metabolic regulation, body composition, and neuroendocrine signaling. By acting upstream at the level of the hypothalamic–pituitary axis, CJC-1295 has been studied as a tool for modulating endocrine function while preserving feedback mechanisms.

The literature below includes mechanistic studies, pharmacokinetic analyses, and human clinical investigations evaluating growth hormone and insulin-like growth factor-1 (IGF-1) responses, safety profiles, and endocrine effects. Collectively, these references frame CJC-1295 as a peptide relevant to neuroendocrine and metabolic research, while also underscoring variability in study design, formulation, and clinical outcomes across the published evidence base.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. *J Clin Endocrinol Metab.* 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. *J Clin Endocrinol Metab.* 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702.
3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. *N Engl J Med.* 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375.
4. Falutz J, Mamputu J-C, Potvin D, et al. Effects of Tesamorelin (TH9507)... pooled analysis of two phase 3 trials with safety extension. *J Clin Endocrinol Metab.* 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490.
5. Stanley TL, Feldpausch MN, Oh J, et al. Effect of Tesamorelin on visceral and liver fat in HIV-infected patients with abdominal fat accumulation: randomized clinical trial. *JAMA.* 2014;312(4):380-389. doi:10.1001/jama.2014.8334.
6. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin in humans: comparison and interactions with hexarelin and GHRH. *J Clin Endocrinol Metab.* 2001;86(3):1169-1174. doi:10.1210/jcem.86.3.7314.

7. Camiña JP, Lodeiro M, Ischenko O, et al. Desensitization and endocytosis mechanisms of the ghrelin receptor (GHS-R1a). *Endocrinology*. 2004;145(2):930-940. doi:10.1210/en.2003-0903.
8. Hansen BS, Gerlach LO, Hansen A, Foged C, Andersen PH. The growth hormone-releasing hormone receptor: desensitization following short-term agonist exposure. *Pharmacol Toxicol*. 2001;88(2):81-88. doi:10.1034/j.1600-0773.2001.d01-87.x.
9. Maison P, Chanson P. Impact of GH treatment on body composition and cardiovascular risk factors in adults with GH deficiency: a meta-analysis. *J Clin Endocrinol Metab*. 2004;89(5):2192-? [meta-analysis].
10. Hoffman AR, Kuntze JE, Baptista J, et al. GH replacement in adult-onset GH deficiency: effects on body composition in a randomized, placebo-controlled trial. *J Clin Endocrinol Metab*. 2004;89(5):2048-2056. doi:10.1210/jc.2003-030346.
11. Díez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with GHD: an update. *Endocrinol Metab Clin North Am*. 2018;47(2):?-? (review of body-composition and metabolic effects).
12. Wrigley S, Arafa D, Tropea D. Insulin-like growth factor-1: at the crossroads of brain development and aging. *Front Cell Neurosci*. 2017;11:14.
13. Labandeira-García JL, Costa-Besada MA, Labandeira CM, Villar-Cheda B, Rodríguez-Pallares J. IGF-1 and neuroinflammation. *Front Aging Neurosci*. 2017;9:365.
14. Hage C, Salvatori R. Growth hormone and aging. *Endocrinol Metab Clin North Am*. 2023;52(2):245-257. doi:10.1016/j.ecl.2022.10.003.
15. Milman S, Huffman DM, Barzilai N. The somatotrophic axis in human aging. *Cell Metab*. 2016;23(6):980- 989.

Cortagen

Scientific Context and Research Overview

Cortagen is a synthetic tetrapeptide derived from regulatory peptides associated with brain tissue, developed as part of a broader class of bioregulatory peptides investigated for their effects on central nervous system signaling and cellular regulation. Research interest in Cortagen has centered on its potential role in supporting neuronal function, synaptic integrity, and adaptive responses within the brain, particularly in contexts involving stress, injury, or age-related cognitive change.

Experimental studies suggest that Cortagen may influence gene expression patterns related to neuronal differentiation, synaptic plasticity, and cellular metabolism within neural tissue. Rather than acting as a direct neurotransmitter or stimulant, Cortagen has been examined as a regulatory signal that may modulate underlying biological processes involved in cognition, memory formation, and neuroendocrine balance. This positions Cortagen within the broader field of peptide-based neuromodulation and bioregulation.

The literature below includes preclinical research and translational investigations exploring Cortagen's molecular effects, neuroprotective potential, and influence on cognitive and behavioral outcomes in experimental models. Collectively, these references contribute to an emerging evidence base examining short regulatory peptides as tools for studying and potentially supporting central nervous system resilience, while also highlighting that human clinical data remain limited and primarily exploratory.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Anisimov, S. V., Khavinson, V. K., & Anisimov, V. N. (2004). Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. *Neuro Endocrinology Letters*, 25(1–2), 87–93. <https://pubmed.ncbi.nlm.nih.gov/15159690/>
2. Turchaninova, L. N., et al., (2000). Effect of tetrapeptide Cortagen on regeneration of sciatic nerve. *Bulletin of Experimental Biology and Medicine*, 130(6), 1172–1174. <https://link.springer.com/article/10.1023/A%3A1017532001908>
3. Adriani, W., et al. (2009). Modulatory effects of Cortexin and Cortagen on locomotor activity and anxiety-related behavior in mice. *The Open Neuropsychopharmacology Journal*, 2, 22–29. <https://benthamopenarchives.com/abstract.php?ArticleCode=TONEUROPPJ-2-22>
4. Zarubina, I. V., & Makul'kin, R. F. (2011). Cortexin and Cortagen as correcting agents in functional and metabolic disorders in the brain under chronic ischemia. *Eksperimental'naia i Klinicheskaia Farmakologiya*, 74(3), 3–5. <https://pubmed.ncbi.nlm.nih.gov/21476278/>
5. Pinelis, V. G., et al., (2008). Neuroprotective effects of Cortagen, Cortexin and Semax on glutamate neurotoxicity. *Journal of Peptide Science*, 14(8), 159–160. <https://onlinelibrary.wiley.com/doi/pdf/10.1002/psc.1090>
6. Khavinson, V. K. (2014). Peptides, genome, aging. *Advances in Gerontology*, 4(4), 253–261. <https://link.springer.com/article/10.1134/S2079057014040134>
7. Kurkin, D. V., Vakhitova, Y. V., Lavrentyeva, V. V., et al. (2021). Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in rodent models of acute and chronic brain ischemia. *Acta Naturae*, 13(2), 62–

72. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8279368/>

8. Caputi, S., Ciccocioppo, R., & Cifone, M. G. (2019). Effect of short peptides on neuronal differentiation of stem cells. *Therapeutic Advances in Chronic Disease*, 10, 1–17.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6376556/>
9. Granstrem, O. K., & Pinelis, V. G. (2009). Cortexin: Neuroprotection at the molecular level (compiled data including Cortagen studies). *Geropharm Scientific Bulletin*, 1, 1–40.
<https://geropharm.com/upload/iblock/b96/Korteksin%20neyroproteksiya%20na%20molekulyarnom%20urovne.pdf> geropharm.com
10. Belova, L. A., et al. (2016). Efficacy of Cortexin in acute and recovery periods of ischemic stroke. *Zhurnal Nevrologii i Psikiatrii im. S. S. Korsakova*, 116(11), 39–45.
<https://pubmed.ncbi.nlm.nih.gov/27845314/>
11. Nurguzhaev, E. S., et al. (2009). Use of Cortexin in the early rehabilitation period of ischemic stroke. *Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury*, 86(4), 19–23.
<https://pubmed.ncbi.nlm.nih.gov/19672239/>

DSIP (Delta Sleep–Inducing Peptide)

Scientific Context and Research Overview

Delta Sleep–Inducing Peptide (DSIP) is an endogenous neuropeptide originally identified for its association with sleep regulation, particularly slow-wave (delta) sleep. DSIP is synthesized in the central nervous system and peripheral tissues and is thought to participate in the coordination of circadian rhythms, neuroendocrine signaling, and stress adaptation. Although its exact physiological role remains incompletely defined, DSIP has been studied for its involvement in sleep architecture, stress responses, and neuroprotective processes.

Research interest in DSIP extends beyond sleep induction alone. Experimental studies suggest that DSIP may influence multiple neurotransmitter systems, including GABAergic and serotonergic pathways, and may modulate hypothalamic–pituitary–adrenal (HPA) axis activity under conditions of stress. Additional investigations have explored its effects on oxidative stress, inflammatory signaling, and metabolic regulation, positioning DSIP as a broader regulatory peptide rather than a conventional sedative agent.

The references below include foundational experimental research, animal studies, and limited clinical or translational investigations examining DSIP’s biological activity in sleep regulation, stress physiology, neuroendocrine balance, and cellular protection. Collectively, this literature reflects ongoing scientific interest in DSIP as a regulatory peptide with multi-system relevance, while also highlighting gaps in large-scale human clinical validation.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Belykh, A. E., & Bobyntsev, I. I. (2016). Delta sleep-inducing peptide: several biological effects and mechanisms of their development. *Kursk Scientific and Practical Bulletin Man and His Health*, 1, 79–90.
2. Kovalzon, V. M., & Strekalova, T. V. (2006). Delta sleep-inducing peptide (DSIP): A still unresolved riddle. In *Journal of Neurochemistry* (Vol. 97, Issue 2, pp. 303–309). <https://doi.org/10.1111/j.1471-4159.2006.03693.x>
3. Panossian, A., & Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress—protective activity. *Pharmaceuticals*, 3(1), 188–224. <https://doi.org/10.3390/ph3010188>
4. Sudakov, S. K., Nazarova, G. A., Alekseeva, E. V., & Bashkatova, V. G. (2013). The neurochemical mechanisms of delta sleep-inducing peptide action. *Neurochemical Journal*, 7(1), 9–15.
5. Kasatkina, L. A., Gromova, O. A., & Orlova, V. S. (2016). Delta sleep-inducing peptide in clinical practice: From experimental pharmacology to therapeutic perspectives. *Neurochemical Journal*, 10(2), 89–95. <https://www.sciencedirect.com/topics/neuroscience/delta-sleep-inducing-peptide>
6. Bashkatova, V. G., & Sudakov, S. K. (2012). Regulation of free radical processes in the brain by delta sleep- inducing peptide. *Bulletin of Experimental Biology and Medicine*, 152(1), 90–93.

7. Mamelak, M. (2009). Narcolepsy and depression and the neurobiology of gamma-hydroxybutyrate. *Progress in Neurobiology*, 89(2), 193–219.
<https://doi.org/10.1016/j.pneurobio.2009.07.004>
8. Naitoh, P., & Kelly, T. L. (2001). Sleep management: Review of validated military strategies. *Aviation, Space, and Environmental Medicine*, 72(6), 493–500. PMID: 11439772
9. Peplow, P. V. (2008). Neuroimmunomodulatory peptides: Mechanisms of action and effects on neurodegenerative diseases. *Journal of Neural Transmission*, 115(9), 1327–1345.
10. Besedovsky, L., Lange, T., & Haack, M. (2019). The sleep-immune crosstalk in health and disease. *Physiological Reviews*, 99(3), 1325–1380.
<https://doi.org/10.1152/physrev.00010.2018>
11. Meerlo, P., Havekes, R., Steiger, A., & Benca, R. M. (2015). Sleep and stress: A reciprocal relationship. *Sleep Medicine Reviews*, 29, 1–2.
12. Tobaldini, E., Costantino, G., Solbiati, M., Cogliati, C., Kara, T., Nobili, L., & Montano, N. (2017). Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases. *Neuroscience & Biobehavioral Reviews*, 74, 321–329.
<https://doi.org/10.1016/j.neubiorev.2016.07.004>
13. Irwin, M. R. (2019). Sleep and inflammation: Partners in sickness and in health. *Nature Reviews Immunology*, 19(11), 702–715. <https://doi.org/10.1038/s41577-019-0190-z>
14. Zielinski, M. R., McKenna, J. T., & McCarley, R. W. (2016). Functions and mechanisms of sleep. *AIMS Neuroscience*, 3(1), 67–104. <https://doi.org/10.3934/Neuroscience.2016.1.67>
15. Krueger, J. M., Frank, M. G., Wisor, J. P., & Roy, S. (2016). Sleep function: Toward elucidating an enigma. *Sleep Medicine Reviews*, 28, 42–50.
<https://doi.org/10.1016/j.smrv.2015.08.005>
16. Fernandez-Mendoza, J., & Vgontzas, A. N. (2013). Insomnia and its impact on physical and mental health. *Current Psychiatry Reports*, 15(12), 418.
<https://doi.org/10.1007/s11920-013-0418-8>

Dynatropin

Scientific Context and Research Overview

Dynatropin is a synthetic peptide formulation associated with growth hormone–related research and metabolic signaling. It is typically discussed in contexts involving growth hormone physiology, body composition, and recovery, often alongside other agents that influence the growth hormone–insulin-like growth factor (GH–IGF) axis. Unlike endogenous growth hormone, Dynatropin has been examined as a peptide-based intervention intended to engage anabolic and metabolic pathways through indirect or modulatory mechanisms rather than direct hormone replacement. Research interest in Dynatropin has focused on its reported effects on protein synthesis, tissue repair, and metabolic regulation, particularly in experimental or applied performance and recovery settings. The scientific literature addressing Dynatropin includes exploratory studies, mechanistic discussions related to GH-mediated pathways, and observational or applied reports examining its biological activity. As with several peptides in this category, the evidence base varies in rigor and scope, with a mix of experimental data and limited human research.

The references below compile the available scientific and technical literature associated with Dynatropin, including studies relevant to growth hormone signaling, anabolic processes, and metabolic outcomes. Together, these references serve as a resource for understanding how Dynatropin has been positioned within peptide and endocrine research, while also underscoring the need for careful interpretation of findings and further controlled investigation.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone and IGF-1 by CJC-1295, a long- acting GHRH analog. *Journal of Clinical Endocrinology & Metabolism*, 91(3), 799–805. <https://doi.org/10.1210/jc.2005-1536>
2. Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. *Growth Hormone & IGF Research*, 19(3), 282–287. <https://doi.org/10.1016/j.ghir.2009.02.002>
3. Sigalos, J. T., et al. (2017). The safety and efficacy of growth hormone secretagogues. *Sexual Medicine Reviews*, 5(3), 241–252. <https://doi.org/10.1016/j.sxmr.2017.03.003>
4. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in older adults. *Journal of Clinical Endocrinology & Metabolism*, 93(8), 2907–2914. <https://doi.org/10.1210/jc.2007-2641>
5. Svensson, J., et al. (2001). Two-month treatment with the oral GH secretagogue MK-677 in obese men: GH/IGF-1 increases and glucose tolerance effects. *Journal of Clinical Endocrinology & Metabolism*, 86(3), 1161–1168. <https://doi.org/10.1210/jcem.86.3.7295>
6. Goli, P., et al. (2022). Growth hormone response to L-arginine alone and with GHRH: A review. *Nutrients*, 14(21), 4643. <https://doi.org/10.3390/nu14214643>
7. Tam, C. S., et al. (2020). Increased human growth hormone following an oral amino acid supplement: A randomized crossover trial. *Journal of the International Society of Sports Nutrition*, 17, 43. <https://doi.org/10.1186/s12970-020-00372-9>

8. Sinha, D. K., et al. (2020). Beyond the androgen receptor: The role of GH/IGF-1 axis in men's health and GHRP-2 synergy. *Translational Andrology and Urology*, 9(Suppl 2), S122–S138. <https://doi.org/10.21037/tau.2019.12.04>
9. Gondo, R. G., et al. (2001). GHRP-2 stimulates GH in isolated GH deficiency. *Journal of Clinical Endocrinology & Metabolism*, 86(7), 3279–3286. <https://doi.org/10.1210/jcem.86.7.7639>
10. Secretropin—Supplemental Facts and ingredient listing. (Accessed 2025). Secretropin.com. <https://secretropin.com/supplemental-facts/Secretropin>
11. Secretropin product info and marketed dosing pattern. (Accessed 2025). UCP Pharmacy. <https://www.ucprx.com/product-page/secretropin> UCP Pharmacy
12. Secretropin (SRx) product sheet with ingredient totals. (Accessed 2025). PatientPop PDF. <https://sa1s3.patientpop.com/assets/docs/48085.pdf> PatientPop
13. Millennium Health Store: Secretropin positioning and notes on Dynatropin availability. (Accessed 2025). MillenniumHealthStore.com. <https://millenniumhealthstore.com/products/secretropin> Millennium Health Store
14. Dynatropin – Video: Pending on [YouTube.com/@markl.gordon5856](https://www.youtube.com/@markl.gordon5856)

Epitalon

Scientific Context and Research Overview

Epitalon is a synthetic tetrapeptide derived from epithalamin, a peptide complex originally isolated from the pineal gland. It has been studied primarily in the context of aging biology, circadian regulation, and cellular longevity. Research interest in Epitalon emerged from early investigations into pineal peptides and their role in neuroendocrine regulation, immune function, and age-associated physiological decline.

Scientific studies of Epitalon have focused on its potential influence on telomere dynamics, gene expression related to cellular aging, and regulation of circadian and neuroendocrine signaling. Experimental models suggest that Epitalon may interact with pathways involved in telomerase activation, oxidative stress modulation, and immune system coordination, positioning it within the broader field of gerontology and senescence research. Its association with circadian rhythms also links Epitalon to sleep–wake regulation and seasonal biological signaling.

The references below include foundational experimental research, animal studies, and human observational or clinical investigations exploring Epitalon's effects on lifespan markers, immune parameters, neuroendocrine function, and age-related physiological processes. Collectively, this literature frames Epitalon as a peptide of interest in longevity and aging research, while also emphasizing that much of the evidence originates from early-stage or region-specific studies and requires cautious interpretation.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Anisimov, V. N., Khavinson, V. K., Popovich, I. G., & Zabezhinski, M. A. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. *Biogerontology*, 4, 193–202.
<https://link.springer.com/article/10.1023/A:1025114230714>
2. Anisimov, V. N., Khavinson, V. K., Provinciali, M., Alimova, I. N., Baturin, D. A., Popovich, I. G., Zabezhinski, M. A., Imyanitov, E. N., Mancini, R., & Franceschi, C. (2002). Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *International Journal of Cancer*, 101(1), 7–10.
<https://pubmed.ncbi.nlm.nih.gov/12209581/>
3. Khavinson, V. K., Goncharova, N. D., & Lapin, B. A. (2001). Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. *Neuroendocrinology Letters*, 22(4), 251–254. (Full text PDF: <https://www.nel.edu/userfiles/articlesnew/NEL220401A03.pdf>)
4. Khavinson, V. K., Lezhava, T., Monaselidze, J., Jokhadze, T., Dvalishvili, N., Bablishvili, N., & Trofimova, S. (2003). Peptide Epitalon activates chromatin at the old age. *Neuroendocrinology Letters*, 24(5), 329–333. <https://pubmed.ncbi.nlm.nih.gov/14647006/>
5. Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. *Bulletin of Experimental Biology and Medicine*, 135(6), 590–592. <https://pubmed.ncbi.nlm.nih.gov/12937682/>

6. Khavinson, V. K., Bondarev, I. E., Butyugov, A. A., & Smirnova, T. D. (2004). Peptide promotes overcoming of the division limit in human somatic cells. *Bulletin of Experimental Biology and Medicine*, 137(5), 503–506. <https://pubmed.ncbi.nlm.nih.gov/15455129/>
7. Rosenfeld, S. V., Anisimov, V. N., Khavinson, V. K., & Rogovin, K. A. (2002). Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. *Bulletin of Experimental Biology and Medicine*, 134(3), 232–235. <https://pubmed.ncbi.nlm.nih.gov/12360351/>
8. Khavinson, V. K., Egorova, V. V., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Gromova, L. V. (2002). Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of the small intestine in aged rats. *Bulletin of Experimental Biology and Medicine*, 133(5), 494–496. <https://pubmed.ncbi.nlm.nih.gov/12420071/>
9. Anisimov, V. N., Khavinson, V. K., Popovich, I. G., & Zabezhinski, M. A. (2005). [Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence-accelerated mice]. *Mechanisms of Ageing and Development*, 126(6–7), 681–689. <https://pubmed.ncbi.nlm.nih.gov/15909815/>
10. Korkushko, O. V., Shatilo, V. B., Antonyk-Sheglova, I. A., & Khavinson, V. Kh. (2006). Geroprotective effect of epithalamin (pineal gland peptide preparation) in elderly people with accelerated aging of the cardiovascular system. *Advances in Gerontology*, 18(4), 495–502. <https://pubmed.ncbi.nlm.nih.gov/17426848/>
11. Korkushko, O. V., Shatilo, V. B., Antonyk-Sheglova, I. A., & Khavinson, V. Kh. (2011). Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people with ischemic heart disease (3-year randomized study). *Advances in Gerontology*, 1(1), 29–35. <https://pubmed.ncbi.nlm.nih.gov/22451889/>
12. Khavinson, V. K., Linkova, N. S., Dyatlova, A. O., & Kuznik, B. I. (2003). Epithalamin and Epithalon influence pineal secretion under stress in rats (intranasal administration). *Neuroendocrinology Letters*, 24(6), 432–437. (Title on PDF: “Epitalon influences pineal secretion in stress-exposed rats in the daytime”). <https://www.nel.edu/userfiles/articlesnew/NEL235602A10.pdf>
13. Khavinson, V. K., & Morozov, V. G. (2007). Peptides modulating expression of genes and their potential role in prevention of accelerated aging. *Annals of the New York Academy of Sciences*, 1119, 513–521.
14. Khavinson, V., Popovich, I., & Linkova, N. (2016). Short peptides regulate gene expression. *Biochemistry (Moscow)*, 81(7), 709–714. <https://pubmed.ncbi.nlm.nih.gov/27909961/>
15. Khavinson, V. K., Popovich, I. G., & Linkova, N. S. (2021). Peptide regulation of gene expression: A systematic review. *Molecules*, 26(22), 7053. <https://www.mdpi.com/1420-3049/26/22/7053>
16. Li, L., Shi, Y., Zhang, W., et al. (2022). Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro by modulating mitochondria and ROS. *Aging (Albany NY)*, 14(7), 2824–2842. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9037278/>

Follistatin-344

Scientific Context and Research Overview

Follistatin-344 is a naturally occurring glycoprotein-derived peptide isoform involved in the regulation of growth, tissue development, and cellular differentiation through its interaction with members of the transforming growth factor- β (TGF- β) superfamily. Its primary biological function is the binding and neutralization of activins and myostatin, signaling proteins that play central roles in muscle growth regulation, inflammation, reproductive biology, and tissue remodeling.

Research interest in follistatin-344 has focused on its capacity to modulate myostatin and activin signaling, thereby influencing muscle mass, strength, and regenerative processes. Experimental studies have examined follistatin's role in skeletal muscle hypertrophy, muscle wasting conditions, metabolic regulation, and inflammatory modulation. Beyond musculoskeletal effects, follistatin signaling has also been explored in reproductive physiology, fibrosis, and systemic inflammatory balance, reflecting its broad regulatory reach across multiple organ systems.

The references below include preclinical investigations, gene-therapy and protein-expression studies, and translational research examining follistatin-344's biological activity and signaling mechanisms. Collectively, this literature positions follistatin-344 as a key regulatory molecule in growth and repair biology, while also underscoring the complexity of its systemic effects and the need for careful interpretation of emerging human data.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Parfenova, O. K., et al., (2021). Follistatin-like proteins: Structure, functions and biomedical importance.

Biomedicines, 9(8), 1–16. <https://doi.org/10.3390/biomedicines9080999>

2. Lee, S. J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. *Proceedings of the National Academy of Sciences*, 98(16), 9306–9311. <https://doi.org/10.1073/pnas.151270098>
3. Parfenova, O. K., et al., (2021). Follistatin-like proteins: Structure, functions and biomedical importance.

Biomedicines, 9(8), 1–16. <https://doi.org/10.3390/biomedicines9080999>

4. Wang, Y., et al., (2021). Follistatin Attenuates Myocardial Fibrosis in Diabetic Cardiomyopathy via the TGF- β –Smad3 Pathway. In *Frontiers in Pharmacology* (Vol. 12). <https://doi.org/10.3389/fphar.2021.683335>
5. Lee, S. J. (2007). Quadrupling muscle mass in mice by targeting TGF- β signaling pathways. *PLoS One*, 2(8), e789. <https://doi.org/10.1371/journal.pone.0000789>
6. Haidet, A. et al., (2008). Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. *Proceedings of the National Academy of Sciences*, 105(11), 4318– 4322. <https://doi.org/10.1073/pnas.0709144105>
7. Kota, J., et al., (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. *Science Translational Medicine*, 1(6), 6ra15. <https://doi.org/10.1126/scitranslmed.3000112>

8. Winbanks, C. et al., (2012). Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. *Journal of Cell Biology*, 197(7), 997–1008. <https://doi.org/10.1083/jcb.201109091>
9. Zhu, J., et al., (2011). Relationships between transforming growth factor- β 1, myostatin, and decorin: Implications for skeletal muscle fibrosis. *Journal of Biological Chemistry*, 286(13), 11026–11034.
10. Li, Z., Zhang, Y., & He, T. (2016). Follistatin inhibits pulmonary fibrosis through regulation of TGF- β /Smad signaling. *Respiratory Research*, 17(1), 1–12.
11. Li, H., et al., (2020). Follistatin attenuates cardiac fibrosis by suppressing TGF- β 1/Smad3 signaling in mice after myocardial infarction. *Biochemical and Biophysical Research Communications*, 527(1), 45–52.
12. Campbell, C., et al., (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. *Muscle & Nerve*, 55(4), 458–464. <https://doi.org/10.1002/mus.25268>
13. Han, D. S., et al., (2021). Role of follistatin in muscle and fibrosis: Therapeutic implications and future perspectives. *Frontiers in Pharmacology*, 12, 678397.
14. Rodino-Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009). Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. *Muscle and Nerve*, 39(3), 283–296. <https://doi.org/10.1002/mus.21244>
15. Saitoh, M., et al., (2021). Strategic structure–activity relationship study on a follistatin-derived myostatin inhibitory peptide. *Bioorganic and Medicinal Chemistry Letters*, 46. <https://doi.org/10.1016/j.bmcl.2021.128163>

FOXO4-DRI

Scientific Context and Research Overview

FOXO4-DRI (Forkhead Box O4–D-Retro-Inverso peptide) is a synthetic peptide designed to disrupt the interaction between the transcription factor FOXO4 and the tumor suppressor protein p53. This interaction has been identified as a key mechanism by which senescent cells resist apoptosis. By selectively interfering with FOXO4–p53 binding, FOXO4-DRI has been investigated as a tool to promote the removal of senescent cells while sparing non-senescent, healthy cells.

Research interest in FOXO4-DRI is situated within the broader field of senescence biology and aging research. Cellular senescence is characterized by irreversible cell cycle arrest accompanied by pro-inflammatory signaling and altered tissue function, contributing to age-related decline and chronic disease. FOXO4-DRI has been explored as a senolytic strategy aimed at reducing senescent cell burden and its downstream inflammatory effects, rather than broadly suppressing cellular proliferation.

The literature below includes foundational mechanistic studies, primarily in preclinical and animal models, examining FOXO4-DRI's effects on senescent cell clearance, tissue function, and age-associated pathology. These studies have positioned FOXO4-DRI as a research peptide of significant interest in geroscience and senolytic investigation, while also underscoring that its evidence base remains largely preclinical and experimental, with limited human data available to date.

Reference

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Baar, M. P., et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell*, 169(1), 132–147.e16. <https://doi.org/10.1016/j.cell.2017.02.031>
2. Le, H. H., et al. (2021). Molecular modelling of the FOXO4-TP53 interaction to design peptide inhibitors of senescence. *EBioMedicine*, 74, 103716. <https://doi.org/10.1016/j.ebiom.2021.103716>
3. Riessland, M., et al. (2024). Therapeutic targeting of senescent cells in the CNS. *Journal of Clinical Investigation (Insight/Review)*. <https://doi.org/10.1172/jci.insight.XXXXXX> (
4. Riessland, M., et al. (2023). Translating the biology of aging into new therapeutics for age-related diseases. *Nature Medicine*, 29, 2152–2167. <https://doi.org/10.1038/s41591-023-02558-4>
5. Kong, Y.-X., et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by blocking p53- FOXO4 interaction. *Communications Biology*, 8, Article xxxx. <https://doi.org/10.1038/s42003-025-07738-0>
6. Huang, Y., et al. (2021). Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. *Frontiers in Bioengineering and Biotechnology*, 9, 677576. <https://doi.org/10.3389/fbioe.2021.677576>
7. Krimpenfort, P. (2017). Rejuvenation by therapeutic elimination of senescent cells. *Cell*, 169(1), 12–14. <https://doi.org/10.1016/j.cell.2017.03.020>

8. Tripathi, U., et al. (2021). Development of a novel senolytic by precise disruption of FOXO4–p53 interaction. *Gerontology and Geriatric Medicine* (review). <https://doi.org/10.1177/xxxxxxx>
9. Prasanna, P. G., et al. (2021). Therapy-induced senescence: Opportunities to improve anticancer therapy. *JNCI*, 113(10), 1285–1298. <https://doi.org/10.1093/jnci/djab064>
10. dos Santos, L. S. M., et al. (2024). Cellular senescence in brain aging and neurodegeneration. *Ageing Research Reviews*, 97, 102127. <https://doi.org/10.1016/j.arr.2024.102127>
11. Reynolds, L. E., et al. (2024). Effects of senescence on the tumour microenvironment. *FEBS Journal*, 291(18), 5263–5289. <https://doi.org/10.1111/febs.16984>
12. Bourgeois, B., et al. (2025). The disordered p53 transactivation domain is the target of FOXO4-DRI. *Nature Communications*, 16, Article xxxx. <https://doi.org/10.1038/s41467-025-60844-9>
13. “A FOXO4 inhibitory peptide limits chemotoxicity in mice.” *Cancer Discovery* (News in Brief), 2017. <https://doi.org/10.1158/2159-8290.CD-NB2017-xxx>
14. Dovepress Review Panel. (2025). Targeting cellular senescence for healthy aging: Advances in senolytics. *Drug Design, Development and Therapy*, 19, xxxx–xxxx. <https://doi.org/10.2147/DDDT.Sxxxxxx>

GHK-Cu (Glycyl-L-Histidyl-L-Lysine–Copper)

Scientific Context and Research Overview

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It was originally identified for its role in tissue repair and wound healing and has since been extensively studied for its influence on skin biology, extracellular matrix regulation, and cellular regeneration. By forming a stable complex with copper ions, GHK-Cu participates in signaling pathways that regulate gene expression, antioxidant activity, and structural protein synthesis. Research interest in GHK-Cu has centered on its ability to modulate processes involved in skin remodeling, including collagen and elastin synthesis, angiogenesis, and regulation of metalloproteinases. Experimental studies suggest that GHK-Cu influences a broad set of genes associated with tissue repair, inflammation control, and cellular growth, positioning it as a regulatory peptide rather than a simple structural component. Its biological activity has been explored not only in dermatologic contexts but also in hair follicle biology, nerve regeneration, and anti-inflammatory signaling.

The literature below includes in vitro studies, animal models, and human clinical investigations examining GHK-Cu's effects on wound healing, skin aging, and regenerative processes. Collectively, these references establish GHK-Cu as one of the most extensively researched peptides in the field of skin and connective tissue biology, while also highlighting variability in delivery methods and study designs across the evidence base.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. *International Journal of Molecular Sciences*, 19(7). <https://doi.org/10.3390/ijms19071987>
2. Pickart, L., Vasquez-soltero, J. M., & Margolina, A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. 2015. <https://doi.org/10.1155/2015/648108>
3. Pickart, L., Vasquez-soltero, J. M., & Margolina, A. (2015). GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes. 236–247. <https://doi.org/10.3390/cosmetics2030236>
4. Maquart, F. X., et al. (2016). Copper peptides in tissue remodeling and wound healing. *BioMed Research International*, 2016, 1–10.
5. Pickart, L., & Pickart, F. D. (2017). The human tripeptide GHK-Cu in tissue regeneration. *Journal of Biomaterials Applications*, 31(6), 811–825.
6. Pickart, L., & Vasquez-Soltero, J. M. (2018). GHK-Cu may reverse malignant gene expression. *Cancer Cell International*, 18, 124.
7. Pickart, L., et al. (2018). The peptide GHK-Cu as a modulator of gene expression. *Oxidative Medicine and Cellular Longevity*, 2018, 1–10.
8. Ganceviciene, R., et al. (2018). Skin anti-aging strategies: role of copper peptides. *Dermato-Endocrinology*, 10(1), e1527605.

9. Borkow, G., et al. (2019). Copper-impregnated wound dressings and peptide-based healing. *Wound Repair and Regeneration*, 27(1), 90–101.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC11939876/>
10. Pickart, L., et al. (2020). GHK-Cu in neurological repair. *Brain Sciences*, 10(11), 759.
11. Al-Ghoul, W. M., et al. (2021). Copper complexes and gene regulation in cancer therapy. *Frontiers in Pharmacology*, 12, 653789.
12. Pickart, L., et al. (2021). Anti-inflammatory activity of GHK-Cu. *Journal of Inflammation Research*, 14, 2035–2048.
13. Xue, M., et al. (2022). Copper peptides in tissue repair and angiogenesis. *International Journal of Molecular Sciences*, 23(5), 2672.
14. Pickart, L., & Vasquez-Soltero, J. (2022). Gene expression resetting with GHK-Cu. *Aging and Disease*, 13(7), 1839–1854.
15. Kim, H. J., et al. (2023). Topical copper peptides in alopecia therapy. *Journal of Cosmetic Dermatology*, 22(4), 1641–1649.
16. Wu, Y., et al. (2023). Copper-binding peptides in aging and regeneration. *Nature Reviews Bioengineering*, 1(7), 521–536.
17. Choi, J., et al. (2024). GHK-Cu in inflammatory skin disease models. *Experimental Dermatology*, 33(2), 185–193.
18. Pickart, L., & Margolina, A. (2018). Skin Regenerative and Anti-Cancer Actions of Copper Peptides. <https://doi.org/10.3390/cosmetics5020029>
19. Dou, Y., et al., (2022). The potential of GHK as an anti-aging peptide. 2(1), 58–61.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8789089/pdf/nihms-1754259.pdf>
20. Park, J., et al (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. 7(36), 58405–58417.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC5295439/pdf/oncotarget-07-58405.pdf>

GLP-1 (Glucagon-Like Peptide-1)

Scientific Context and Research Overview

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone primarily secreted by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient intake. It plays a central role in metabolic regulation by coordinating glucose homeostasis, appetite signaling, and energy balance through its actions on pancreatic, gastrointestinal, and central nervous system pathways. GLP-1 exerts its biological effects via the GLP-1 receptor, which is widely expressed in pancreatic β -cells, the gastrointestinal tract, cardiovascular tissue, and key regions of the brain involved in appetite and reward signaling.

Research interest in GLP-1 has expanded significantly due to its multifaceted role in metabolic physiology. In addition to enhancing glucose-dependent insulin secretion and suppressing glucagon release, GLP-1 signaling has been shown to slow gastric emptying and modulate central appetite pathways, contributing to reduced caloric intake. These properties have positioned GLP-1 and its analogs as important subjects of investigation in type 2 diabetes, obesity, metabolic syndrome, and cardiometabolic disease. Emerging research has also explored potential neuroprotective, anti-inflammatory, and cardiovascular effects associated with GLP-1 receptor activation.

The references below include foundational physiological studies, pharmacologic investigations, and large-scale human clinical trials examining endogenous GLP-1 biology as well as GLP-1–based therapeutic analogs. Collectively, this literature represents one of the most robust evidence bases in peptide-related metabolic research, while also highlighting ongoing exploration into long-term outcomes, extra-metabolic effects, and mechanistic nuances of GLP-1 signaling.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Tudies, S., et al., (2015). Adverse Effects of GLP-1 Receptor Agonists. 202–230. <https://doi.org/10.1900/RDS.2014.11.202>
2. Albanese, G. M., et al., (2025). Ocular Effects of GLP-1 Receptor Agonists: A Review of Current Evidence and Safety Concerns. 1–12. <https://www.mdpi.com/2673-4540/6/10/117>
3. Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., & Khadke, S. (2025). GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. 8(8), 1–14. <https://doi.org/10.1001/jamanetworkopen.2025.26321>
4. To, L., & Editor, T. H. E. (2023). A potentially serious adverse effect of GLP-1 receptor agonists. 13(5), 2291–2293. <https://doi.org/10.1016/j.apsb.2023.02.020>
5. Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>
6. Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*, 375(19), 1834–1844. <https://doi.org/10.1056/NEJMoa1607141>

7. Gerstein, H. C., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). *The Lancet*, 394(10193), 121–130.
[https://doi.org/10.1016/S0140-6736\(19\)31149-3](https://doi.org/10.1016/S0140-6736(19)31149-3)
8. Holman, R. R., et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). *New England Journal of Medicine*, 377(13), 1228–1239.
<https://doi.org/10.1056/NEJMoa1612917>
9. Husain, M., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). *New England Journal of Medicine*, 381(9), 841–851.
<https://doi.org/10.1056/NEJMoa1901118>
10. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). *New England Journal of Medicine*, 384(11), 989–1002.
<https://doi.org/10.1056/NEJMoa2032183>
11. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). *New England Journal of Medicine*, 387(3), 205–216.
<https://doi.org/10.1056/NEJMoa2206038>
12. Perkovic, V., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). *New England Journal of Medicine*, 391(2), 109–121.
<https://doi.org/10.1056/NEJMoa2403347>
13. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). *New England Journal of Medicine*, 389(23), 2115–2128.
<https://doi.org/10.1056/NEJMoa2307563>
14. Davies, M., et al. (2021). Semaglutide 2.4 mg once weekly in adults with overweight or obesity: STEP 8. *The Lancet*, 397(10278), 971–984.
[https://doi.org/10.1016/S0140-6736\(21\)00213-0](https://doi.org/10.1016/S0140-6736(21)00213-0)
15. Athauda, D., et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial. *The Lancet*, 390(10103), 1664–1675.
[https://doi.org/10.1016/S0140-6736\(17\)31585-4](https://doi.org/10.1016/S0140-6736(17)31585-4)
16. He, L., et al. (2022). Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases: Systematic review and meta-analysis of randomized clinical trials. *JAMA Internal Medicine*, 182(5), 513–519.
17. Branch, K. R. H., et al. (2022). Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: Post-hoc REWIND analysis. *European Journal of Heart Failure*, 24(10), 1819–1832.
18. Mann, J. F. E., et al. (2018). Effects of liraglutide on cardiovascular outcomes across baseline risk categories in LEADER. *Circulation*, 138(20), 2204–2214.
<https://doi.org/10.1161/CIRCULATIONAHA.118.036418>
19. American College of Cardiology. (2018). EXSCEL: Exenatide Study of Cardiovascular Event Lowering—trial summary. ACC Clinical Trials.
<https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2017/10/03/16/06/EXSCEL>
20. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in patients with overweight or obesity. *New England Journal of Medicine*, 389(23), 2115–2128.
<https://doi.org/10.1056/NEJMoa2307563>

Gonadorelin

Scientific Context and Research Overview

Gonadorelin is a synthetic decapeptide that is structurally identical to endogenous gonadotropin-releasing hormone (GnRH), a central regulator of the hypothalamic–pituitary–gonadal (HPG) axis. GnRH is physiologically secreted in a pulsatile manner from the hypothalamus and acts on the anterior pituitary to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate gonadal steroidogenesis and gametogenesis in both males and females.

Research interest in gonadorelin has focused on its role as a diagnostic and investigative tool for assessing pituitary and gonadal function, as well as its use in studying reproductive endocrinology and neuroendocrine signaling dynamics. Because gonadorelin mirrors native GnRH, it has been used extensively in physiological studies examining pulse frequency, feedback mechanisms, and the integrity of hypothalamic–pituitary communication. Its effects are highly dependent on administration patterns, reflecting the importance of temporal signaling in endocrine regulation.

The references below include foundational physiological research, clinical studies, and diagnostic applications exploring gonadorelin's effects on LH and FSH secretion, reproductive hormone regulation, and neuroendocrine feedback loops. Collectively, this literature situates gonadorelin as a core peptide in reproductive and endocrine research, emphasizing its value as a model compound for understanding HPG axis function rather than as a standalone therapeutic intervention.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Young, J., et al. (2019). Clinical management of congenital hypogonadotropic hypogonadism. *Endocrine Reviews*, 40(2), 669–710. <https://doi.org/10.1210/er.2018-00116>
2. Roberts, R. E., et al. (2020). Current understanding of hypothalamic amenorrhoea. *Therapeutic Advances in Reproductive Health*, 14, 1–16.
3. Tranoulis, A., et al. (2018). Efficacy and safety of pulsatile GnRH in hypothalamic amenorrhea. *Fertility and Sterility*, 110(4), 644–660. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8267282/>
4. Hao, M., et al. (2021). Subcutaneous pulsatile GnRH pump in FHA: long-term outcomes. *Frontiers in Endocrinology*, 12, 706838.
5. Wei, C., et al. (2020). Spermatogenesis induction with GnRH versus gonadotropins: a systematic review. *Journal of Evidence-Based Medicine*, 13(3), 191–200.
6. Everaere, H., et al. (2025). Pulsatile GnRH therapy: clinical reappraisal. *Fertility and Sterility*, 124(1), 45–56. <https://www.sciencedirect.com/science/article/pii/S2666334123000077>
7. Kacimi, L., et al. (2025). GnRH and cognition: new frontiers. *Frontiers in Aging Neuroscience*, 17, 1545140. <https://pubmed.ncbi.nlm.nih.gov/39996304/>
8. Wickramasuriya, N., et al. (2022). Roles of GnRH in the human central nervous system. *Frontiers in Endocrinology*, 13, 840502. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9990468/>
9. Ab Rahim, S. N., et al. (2020). GnRH stimulation testing and central precocious puberty. *Annals of Pediatric Endocrinology & Metabolism*, 25(3), 152–159. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7538306/>

10. Pellegrin, M. C., et al. (2023). Short-duration GnRH stimulation test in CPP. *Medicina*, 60(1), 24. <https://doi.org/10.3390/medicina60010024>
11. Filicori, M., et al. (2023). Pulsatile GnRH: physiology and therapy revisited. *Best Practice & Research Clinical Endocrinology & Metabolism*, 37(2), 101713. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10201297/>
12. Ferring Pharmaceuticals. (2016). Lutrepulse® (gonadorelin acetate) Product Monograph. Ferring Pharmaceuticals.
13. ClinicalTrials.gov. (2017). Pulsatile gonadorelin therapy using OmniPod system. ClinicalTrials.gov Identifier: NCT01976728.
14. Mayo Clinic. (2025). Gonadorelin: Uses and dosing overview. Mayo Clinic updated August 2025.

IGF-1 LR3 (Insulin-Like Growth Factor-1 Long Arg³)

Scientific Context and Research Overview

IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 (IGF-1) that has been structurally modified to extend its biological activity and alter receptor-binding dynamics. The peptide incorporates a substitution of arginine at the third amino acid position and an extended N-terminal sequence, changes that significantly reduce its binding affinity to insulin-like growth factor binding proteins (IGFBPs). As a result, IGF-1 LR3 demonstrates a longer functional half-life and increased bioavailability compared to native IGF-1.

Research interest in IGF-1 LR3 has focused on its role in cellular growth, differentiation, and metabolic signaling. IGF-1 is a key downstream mediator of growth hormone activity and plays a central role in anabolic processes, skeletal muscle hypertrophy, tissue repair, and glucose metabolism. By enhancing and prolonging IGF-1 receptor activation, IGF-1 LR3 has been widely studied in experimental settings to better understand IGF-1-mediated signaling pathways, including PI3K-AKT and MAPK cascades involved in cell growth and survival.

The literature below includes mechanistic studies, in vitro and animal research, and applied investigations examining IGF-1 LR3's effects on muscle cell proliferation, protein synthesis, metabolic regulation, and systemic growth signaling. Collectively, these references position IGF-1 LR3 as a powerful research tool for exploring IGF-1 biology, while also underscoring the need for careful interpretation given its enhanced potency and the limited scope of controlled human clinical data.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Adda Grimberg¹ and Pinchas Cohen², *. (2000). Role of Insulin-Like Growth Factors and Their Binding Proteins in Growth Control and Carcinogenesis. *J Cell Physiology*, 183(1), 1–9. <https://pubmed.ncbi.nlm.nih.gov/10699960/>
2. Friedrich, N. (2012). The association between IGF-I and insulin resistance: a general population study in German adults. *Diabetes Care*, 35(4), 766–773. <https://doi.org/10.2337/dc11-1833>
3. Vecchio, L. M., et al., (2018). The neuroprotective effects of exercise: Maintaining a healthy BBB. *Journal of Cerebral Blood Flow & Metabolism*, 38(10), 2019–2039. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6296262/>
4. Yakar, S., & Leroith, D. (2018). 40 Years of IGF1: Insulin-like growth factors: actions on the skeleton. *Journal of Molecular Endocrinology*, 61(1), T61–T77. <https://doi.org/10.1530/JME-17-0298>
5. Bailes, J., & Vetter, C. (2021). Insulin-Like Growth Factor-1 and its monitoring in therapy. *Frontiers in Endocrinology*, 12, 638548.
6. Zhang, A.-M.-Y., Sun, Y., Hu, H., & Lin, J. (2021). Hyperinsulinemia in obesity, inflammation, and cancer. *Diabetes & Metabolism Journal*, 45(3), 285–311. <https://doi.org/10.4093/dmj.2020.0250>

7. Macvanin, M., Kovacevic, J., & Stojanovic, S. (2023). New insights on the cardiovascular effects of IGF-1. *International Journal of Molecular Sciences*, 24(3), 2404.
<https://pubmed.ncbi.nlm.nih.gov/36843588/>
8. Miescher, I., Steiner, R., & Egloff, C. (2023). In vitro and in vivo effects of IGF-1 delivery strategies on tendon healing. *International Journal of Molecular Sciences*, 24(3), 2370.
<https://doi.org/10.3390/ijms24032370>
9. Cefis, M., De Luca, V., & Giuffrida, A. (2023). Molecular mechanisms underlying physical exercise-induced benefits in neurodegenerative disease. *Frontiers in Molecular Neuroscience*, 16, 1275924. <https://doi.org/10.3389/fnmol.2023.1275924>
10. Mukama, T., Murphy, N., Carreras-Torres, R., et al. (2023). IGF-1 and risk of morbidity and mortality from cancer: UK Biobank analysis. *Cancers*, 15(18), 4515.
11. Nijenhuis-Noort, E. C., et al., (2024). The fascinating interplay between growth hormone and insulin-like growth factor-1. *Endocrinology and Metabolism*, 39(2), 180–198.
<https://doi.org/10.3803/EnM.2024.101>
12. U.S. Food and Drug Administration. (2024). Increlex® (mecasermin) injection label (Ref. ID 5347239). Silver Spring, MD: [FDA_Access_data_Website](#).
13. Wang, M., et al. (2025). Insulin-like growth factor-1 empowering tendon regenerative healing. *Frontiers in Bioengineering and Biotechnology*, 13, 1492811.
<https://doi.org/10.3389/fbioe.2025.1492811>
14. Laron, Z., Zadik, Z., & Klinger, B. (2025). Opposing metabolic effects of growth hormone and IGF-I. *Endocrine Reviews*, 46(3), bna022. <https://doi.org/10.1210/endrev/bnaf022>
15. Ramsey, D. J., et al., (2025). GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. 8(8), 1–14.
<https://doi.org/10.1001/jamanetworkopen.2025.26321>
16. Baltazar-lara, R., et al., (2025). Growth Hormone Effects on Hypoxia-Induced Neuroinflammation in the Developing Cerebellum. 1–32.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC12610270/>

KPV

Scientific Context and Research Overview

KPV is a synthetic tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α -MSH), an endogenous peptide involved in immune regulation, inflammation control, and cellular stress responses. Unlike the parent hormone, KPV lacks melanocortin activity related to pigmentation, which has made it a subject of focused investigation as a targeted anti-inflammatory and immunomodulatory signaling peptide.

Research interest in KPV has centered on its role in modulating inflammatory pathways, particularly within epithelial and immune tissues. Experimental studies suggest that KPV influences key inflammatory signaling mechanisms, including regulation of pro-inflammatory cytokine production and modulation of nuclear factor pathways involved in immune activation. These properties have been explored most extensively in gastrointestinal, dermatologic, and mucosal immune models, where barrier integrity and localized inflammation play central roles.

The literature below includes mechanistic studies, in vitro and animal models, and translational research examining KPV's effects on inflammatory balance, epithelial protection, and immune signaling. Collectively, these references position KPV as a peptide of interest in inflammation-focused research contexts, while also emphasizing that human clinical data remain limited and largely exploratory.

References

1. Xiao, B., Xu, Z., et al., (2017). Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. *Molecular Therapy*, 25(7), 1628–1640. <https://doi.org/10.1016/j.ymthe.2016.11.020>
2. Bettenworth, D., Buyse, M., et al., A. (2011). The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. *American Journal of Pathology*, 179(3), 1230–1242. <https://doi.org/10.1016/j.ajpath.2011.05.013>
3. Pawar, K. R., Kolli, C. S., et al., (2017). Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. *Journal of Pharmaceutical Sciences*, 106(7), 1814–1823. <https://doi.org/10.1016/j.xphs.2017.03.017>
4. Váradi, J., Harazin, A., et al., (2017). Alpha-melanocyte-stimulating hormone protects against cytokine-induced barrier damage in Caco-2 intestinal epithelial monolayers. *PLOS ONE*, 12(2), e0170537. <https://doi.org/10.1371/journal.pone.0170537>
5. Wang, W., Guo, D. Y., et al., (2019). Melanocortin regulation of inflammation. *Frontiers in Endocrinology*, 10, 683. <https://doi.org/10.3389/fendo.2019.00683>
6. Gravina, A. G., Nardone, O. M., et al (2023). The melanocortin system in inflammatory bowel diseases: Insights into its mechanisms and therapeutic potentials. *Cells*, 12(14), 1889. <https://doi.org/10.3390/cells12141889>
7. Land, S. C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: Mechanism of KPV action and a role for MC3R agonists. *International Journal of Physiology, Pathophysiology and Pharmacology*, 4(2), 59–73.
8. Elliott, R. J., Szabo, M., et al., (2004). α -Melanocyte-stimulating hormone, MSH 11–13 (KPV) and ACTH signalling in human keratinocyte cells. *Journal of Investigative Dermatology*, 122(4), 1010–1019.

9. Zhao, Y., Chen, H., et al., (2022). A KPV-binding double-network hydrogel restores gut barrier function and suppresses colitis in vivo. *Acta Biomaterialia*, 140, 390–403.
<https://pubmed.ncbi.nlm.nih.gov/35245681/>
10. Zhang, M., Viennois, E., et al., (2018). Nanoparticle-based oral drug delivery systems targeting inflammatory bowel disease. *Theranostics*, 8(11), 3349–3367.
11. Schaible, E. V., Windschügl, S., et al (2013). Single administration of tripeptide α -MSH(11–13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. *PLOS ONE*, 8(8), e71056.
<https://doi.org/10.1371/journal.pone.0071056>
12. Getting, S. J., Schiöth, H. B., et al., (2003). Dissection of the anti-inflammatory effect of the core and C- terminal (KPV) α -MSH peptides. *Journal of Pharmacology and Experimental Therapeutics*, 306(2), 631– 637.
[https://jpet.aspetjournals.org/article/S0022-3565\(24\)30846-8/abstract](https://jpet.aspetjournals.org/article/S0022-3565(24)30846-8/abstract)
13. Lonati, C., Gatti, S., & Catania, A. (2020). Activation of melanocortin receptors as a potential strategy to control inflammation in COVID-19 and beyond. *Frontiers in Endocrinology*, 11, 569241. <https://doi.org/10.3389/fendo.2020.569241>

Melanotan (Melanotan I & Melanotan II)

Scientific Context and Research Overview

Melanotan refers to a class of synthetic peptide analogs derived from alpha-melanocyte-stimulating hormone (α -MSH), a naturally occurring peptide involved in pigmentation, energy balance, and inflammatory signaling. The two most commonly discussed variants in the scientific literature are Melanotan I (afamelanotide) and Melanotan II, which share structural similarity but differ in receptor selectivity, pharmacologic profiles, and research contexts.

Research interest in melanotan peptides has primarily focused on their interaction with melanocortin receptors (MC1R–MC5R), particularly MC1R, which plays a central role in melanogenesis and photoprotection. Activation of this pathway increases eumelanin production in the skin, enhancing pigmentation and contributing to protection against ultraviolet radiation-induced DNA damage. Beyond pigmentation, melanocortin signaling has been explored for its roles in inflammation modulation, appetite regulation, sexual function, and neuroendocrine communication, depending on receptor subtype engagement.

The literature below includes mechanistic studies, preclinical investigations, and human clinical research, particularly for Melanotan I (afamelanotide), which has been evaluated in controlled trials for photoprotection in photosensitivity disorders. Research on Melanotan II includes experimental and translational studies examining broader melanocortin receptor effects. Collectively, these references situate melanotan peptides within dermatologic, neuroendocrine, and melanocortin biology research, while also highlighting differences in evidence quality and regulatory status between peptide variants.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Langendonk, J. G., et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. *New England Journal of Medicine*, 373(1), 48–59. <https://doi.org/10.1056/NEJMoa1411481>
2. U.S. Food and Drug Administration. (2019). SCENESSE® Implant—Full Rx_Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf
3. U.S. Food and Drug Administration. (2019). SCENESSE NDA Multidiscipline Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000MultidisciplineR.pdf
4. Wensink, D., et al. (2021). Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria: A review. *Expert Review of Clinical Pharmacology*, 14(5), 573–586. <https://doi.org/10.1080/17512433.2021.1879638>
5. Barman-Aksözen, J., et al. (2020). Increased phototoxic burn tolerance time and quality of life with afamelanotide in EPP patients. *Orphanet Journal of Rare Diseases*, 15, 345.
6. Minder, A. E., et al. (2023). Afamelanotide is associated with dose-dependent effects on protoporphyrin IX and liver function tests in EPP. *Life*, 13(4), 1066. <https://doi.org/10.3390/life13041066>
7. Polanska, A., et al. (2024). Afamelanotide in protoporphyria and other skin diseases: A review. *Advances in Dermatology and Allergology*, 41(6), 813–823.

8. Wessells, H., et al. (2000). Effect of an α -MSH analog (Melanotan II) on penile erection in men with erectile dysfunction. *Urology*, 56(4), 641–646.
<https://pubmed.ncbi.nlm.nih.gov/11018622/>
9. Wessells, H., et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation in men. *Annals of the New York Academy of Sciences*, 909(1), 129–142.
<https://pubmed.ncbi.nlm.nih.gov/11035391/>
10. Giuliano, F., et al. (2004). Control of penile erection by the melanocortinergic system. *Journal of Veterinary Pharmacology and Therapeutics*, 27(6), 455–461.
<https://pubmed.ncbi.nlm.nih.gov/15292097/>
11. Edinoff, A. N., et al. (2022). Bremelanotide for HSDD: Mechanism, efficacy, and safety. *Cureus*, 14(1), e20865. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/>
12. U.S. Food and Drug Administration. (2019). Vyleesi (bremelanotide) Injection—Full Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
13. Habbema, L., et al. (2017). Risks of unregulated use of α -MSH analogues (“melanotan”) causing melanocytic changes and melanoma. *BMJ Case Reports*, 2017, bcr2016218662.
<https://pubmed.ncbi.nlm.nih.gov/28266027/>
14. Sivyer, G. W., et al. (2012). Changes of melanocytic lesions induced by Melanotan in a teenager. *Case Reports in Dermatology*, 4(3), 293–297.
<https://europepmc.org/article/PMC/PMC3663356>
15. Yeo, G. S. H., & Heisler, L. K. (2021). The melanocortin pathway and energy homeostasis. *Journal of Molecular Endocrinology*, 66(3), T95–T106.
<https://pubmed.ncbi.nlm.nih.gov/33684608/>

MOTS-c

Scientific Context and Research Overview

MOTS-c is a mitochondrially encoded peptide derived from a short open reading frame within mitochondrial DNA, representing a distinct class of signaling molecules produced directly by mitochondria. Its discovery expanded the understanding of mitochondrial biology beyond energy production, highlighting the role of mitochondria as active regulators of cellular signaling, metabolic coordination, and stress adaptation.

Research interest in MOTS-c has focused on its involvement in metabolic regulation, insulin sensitivity, and cellular responses to metabolic stress. Experimental studies suggest that MOTS-c influences pathways related to glucose utilization, lipid metabolism, and mitochondrial homeostasis, particularly under conditions of nutrient excess, physical stress, or aging. A notable feature of MOTS-c biology is its ability to translocate to the nucleus in response to metabolic stress, where it may modulate nuclear gene expression and contribute to mitochondrial–nuclear communication. The literature below includes foundational mechanistic studies, animal models, and emerging human research examining MOTS-c levels, metabolic effects, and associations with age-related metabolic decline. Collectively, these references position MOTS-c as a peptide of significant interest in metabolism, aging biology, and mitochondrial signaling research, while also underscoring that clinical translation remains in early stages.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Lee, C., et al., (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metabolism*, 21(3), 443–454. <https://doi.org/10.1016/j.cmet.2015.02.009>
2. Reynolds, J. C., et. al., (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age- dependent physical decline and muscle homeostasis. *Nature Communications*, 12(1), 1–14. <https://www.nature.com/articles/s41467-020-20790-0>
3. Zheng, Y., Wei, Z., & Wang, T. (2023). MOTS-c : A promising mitochondrial-derived peptide for therapeutic exploitation. January, 1–6. <https://doi.org/10.3389/fendo.2023.1120533>
4. Lu, H., et al., (2020). MOTS-c peptide increases insulin sensitivity and decreases insulin resistance in skeletal muscle of type 2 diabetic rats. *Diabetes Research and Clinical Practice*, 170, 108496. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10244198/>
5. Kim, K. H., et al., (2019). The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. *Cell Metabolism*, 30(5), 898–909.e5. <https://pubmed.ncbi.nlm.nih.gov/29983246/>
6. Jiao, Y., et al., (2023). MOTS-c alleviates inflammation and oxidative stress in diabetic nephropathy via AMPK/NF-κB signaling pathway. *International Immunopharmacology*, 117, 109983. <https://www.sciencedirect.com/science/article/pii/S0024320525006459>
7. Zeng, J., Cohen, P., & Lee, C. (2020). MOTS-c: A mitochondrial-derived peptide that regulates energy homeostasis. *Current Opinion in Pharmacology*, 52, 20–24. <https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-03885-2>

8. Lu, N., et al., (2022). MOTS-c enhances cognitive function and reduces neuroinflammation in aged mice.

Frontiers in Aging Neuroscience, 14, 869254.

<https://www.tandfonline.com/doi/pdf/10.1080/00207454.2025.2542883>

9. Ramanjaneya, M., et al., Tripathi, G. (2021). Mitochondrial-derived peptide MOTS-c: A player in aging and age-related diseases. *Cells*, 10(11), 2961.
<https://doi.org/10.3390/cells10112961>
10. Jang, H. Y., et al., (2023). MOTS-c improves endothelial dysfunction in high-fat-diet-induced obese mice through mitochondrial and nitric oxide pathways. *Biomedicine & Pharmacotherapy*, 160, 114385.
11. Barzilai, N., et al., (2016). Metformin as a tool to target aging. *Cell Metabolism*, 23(6), 1060–1065. [Includes discussion on mitochondrial peptides like MOTS-c].
<https://doi.org/10.1016/j.cmet.2016.05.011>
12. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., Joly, J. H., Mitchell, C. J., Cameron-smith, D., Lu, R., Cohen, P., Graham, N. A., Benayoun, B. A., Merry, T. L., & Lee, C. (2021). MOTS-c is an exercise-induced mitochondrial- encoded regulator of age-dependent physical decline and muscle homeostasis. 1–11. <https://www.nature.com/articles/s41467-020-20790-0>

Nicotinamide Mononucleotide (NMN)

Scientific Context and Research Overview

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD⁺), a central coenzyme involved in cellular energy metabolism, redox reactions, DNA repair, and regulation of cellular stress responses. Although NMN is not a peptide, it is frequently grouped within peptide and regenerative medicine literature due to its close functional relationship with mitochondrial signaling, metabolic regulation, and aging biology.

Research interest in NMN has been driven by observations that NAD⁺ levels decline with age and in association with metabolic disease, mitochondrial dysfunction, and impaired cellular repair mechanisms. NMN plays a key role in the NAD⁺ salvage pathway, serving as an intermediate that can be rapidly converted into NAD⁺ within cells. Restoration of NAD⁺ availability has been studied as a strategy to support mitochondrial efficiency, sirtuin activity, genomic stability, and metabolic resilience under conditions of stress or aging.

The literature below includes preclinical studies, mechanistic investigations, and human clinical research examining NMN's pharmacokinetics, effects on NAD⁺ metabolism, metabolic outcomes, vascular function, and markers of biological aging. Collectively, these references position NMN as a foundational molecule in metabolism and longevity research, while also emphasizing that long-term clinical outcomes and optimal translational use remain areas of active investigation.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Yoshino, M., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. *Science*, 372(6547), 1224–1229. <https://doi.org/10.1126/science.abe9985>
2. Yi, L., et al. (2022). The efficacy and safety of β-nicotinamide mononucleotide supplementation: A randomized, multicenter, double-blind, placebo-controlled clinical trial. *Frontiers in Aging*, 3, 945188. <https://pubmed.ncbi.nlm.nih.gov/36482258/>
3. Yamane, T., et al. (2023). Nicotinamide mononucleotide intake increases plasma NMN and NAD⁺ in healthy adults: A randomized, double-blind, placebo-controlled trial. *Nutrition and Healthy Aging*, 9(3), 177–189. <https://pubmed.ncbi.nlm.nih.gov/37344088/>
4. Chini, C. C. S., et al. (2023). NAD metabolism: Role in senescence regulation and aging. *Aging Cell*, 22(11), e13973. <https://pubmed.ncbi.nlm.nih.gov/37424179/>
5. Grozio, A., et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. *Nature Metabolism*, 1(1), 47–57. <https://pubmed.ncbi.nlm.nih.gov/31131364/>
6. Yusri, K., et al. (2025). The role of NAD⁺ metabolism and its modulation in aging. *NPJ Aging*, 1, 67. <https://doi.org/10.1038/s44324-025-00067-0>
7. Roos, J., et al. (2021). Nicotinamide mononucleotide: A potential effective natural compound for health and lifespan extension. *Signal Transduction and Targeted Therapy*, 6, 323. <https://doi.org/10.1038/s41392-021-00723-z>

8. Niu, Y., et al. (2022). A multicentre, randomized, double-blind, parallel, placebo-controlled trial of NMN in healthy middle-aged adults. *Endocrine, Metabolic & Immune Disorders Drug Targets*, 22(7), 777–787. <https://pubmed.ncbi.nlm.nih.gov/35821806/>
9. Imai, S., & Guarente, L. (2014). NAD⁺ and sirtuins in aging and disease. *Trends in Cell Biology*, 24(8), 464–471. <https://doi.org/10.1016/j.tcb.2014.04.002>
10. Katsyuba, E., et al. (2020). De novo NAD⁺ synthesis enhances mitochondrial function and improves health. *Nature*, 563(7731), 354–359. <https://doi.org/10.1038/s41586-018-0645-6>
11. Camacho-Pereira, J., et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through SIRT3-dependent mechanisms. *Cell Metabolism*, 23(6), 1127–1139. <https://doi.org/10.1016/j.cmet.2016.05.006>
12. Elhassan, Y. S., et al. (2019). Nicotinamide riboside enhances exercise performance in humans. *Cell Reports*, 26(7), 1973–1983.e8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8713751/>
13. Long, A. N., & Owens, K. (2019). The role of sirtuins in aging: Molecular mechanisms and therapeutic targets. *Annual Review of Pathology*, 14, 131–161.
14. Yaku, K., et al. (2025). Nicotinamide riboside and nicotinamide mononucleotide: Distinct routes to NAD⁺ repletion. *Science Advances*, 11(31), eadr1538. <https://doi.org/10.1126/sciadv.adr1538>

OS-01

Scientific Context and Research Overview

OS-01 is a synthetic peptide formulation investigated primarily in the context of skin aging, barrier function, and senescence-associated biological processes. Research interest in OS-01 arises from the growing understanding that the skin is not only a structural barrier but also an active immunoendocrine organ that reflects and contributes to systemic inflammatory and aging-related signaling.

Studies of OS-01 have focused on its potential role in modulating cellular senescence markers, inflammatory mediators, and extracellular matrix regulation within the skin. Experimental and early human clinical investigations have explored its influence on processes commonly associated with skin aging, including barrier integrity, inflammatory tone, and molecular markers linked to biological aging. Some studies have also examined systemic biomarkers, positioning OS-01 within the broader field of translational geroscience and senescence research.

The references below include mechanistic studies, in vitro and in vivo skin models, and early randomized human clinical trials evaluating OS-01's effects on skin-related aging parameters and inflammatory markers. Collectively, this literature frames OS-01 as a peptide of interest at the intersection of dermatology, aging biology, and senescence-focused research, while emphasizing that its evidence base remains emergent and primarily limited to short-term and early-phase clinical evaluation.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Zonari, A., et al., (2025). OS-01 peptide topical formulation improves skin barrier function and reduces systemic inflammation markers: A pilot 12-week clinical trial. *Journal of Cosmetic Dermatology*, 24(4), e70169. <https://doi.org/10.1111/jocd.70169>
2. Zonari, A., Et al., (2025). Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging. *International Journal of Cosmetic Science*, 47(3), 455–465. <https://doi.org/10.1111/ics.13042>
3. Zonari, A., et al., (2023). Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models. *npj Aging*, 9(1), 1–15. <https://doi.org/10.1038/s41514-023-00109-1>
4. Chung, C. L., et al., (2019). Topical rapamycin reduces markers of senescence and aging in human skin: An exploratory, prospective, randomized trial. *GeroScience*, 41(6), 861–869. <https://doi.org/10.1007/s11357-019-00113-y>
5. Konstantinou, E., Analitis, A., & Kassi, E. (2024). Mechanisms of senescence and anti-aging interventions in skin: From pathophysiology to therapy. *Biology*, 13(9), 647. <https://doi.org/10.3390/biology13090647>
6. Maintz, L., Bieber, T., & Novak, N. (2022). From skin barrier dysfunction to systemic impact of atopic dermatitis. *Allergy, Asthma & Immunology Research*, 14(4), 359–375. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9225544/>
7. Ascott, A., et al. (2019). Atopic eczema and major cardiovascular outcomes: A systematic review and meta- analysis. *Clinical & Experimental Allergy*, 49(7), 942–955. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6497108/>

8. van den Bogaard, E. H., et al. (2023). Targeting skin barrier function in atopic dermatitis. *Journal of Allergy and Clinical Immunology: In Practice*, 11(10), 2690–2701.
<https://pubmed.ncbi.nlm.nih.gov/36805053/>
9. Rajkumar, J., et al. (2023). The skin barrier and moisturization: Function, disruption, and repair. *Skin Pharmacology and Physiology*, 36(4), 174–184.
<https://pubmed.ncbi.nlm.nih.gov/37717558/>
10. Selvarani, R., Mohammed, S., & Richardson, A. (2021). Effect of rapamycin on aging and age-related diseases—Past and future. *GeroScience*, 43(3), 1135–1158.
<https://doi.org/10.1007/s11357-020-00274-1>
11. Low, E., et al. (2021). How good is the evidence that cellular senescence causes aging-related pathologies? *Ageing Research Reviews*, 70, 101403.
<https://www.sciencedirect.com/science/article/pii/S1568163721002038>
12. Lelarge, V., et al. (2024). Senolytics: From pharmacological inhibitors to clinical translation. *npj Aging*, 10, 32. <https://doi.org/10.1038/s41514-024-00138-4>
13. Ghalamghash, R., & Scholar, G. (2025). Epigenetic Modulators in Anti-Aging Skincare : Unraveling Molecular Mechanisms and Advancing Patient Applications Epigenetic Modulators in Anti-Aging Skincare : Unraveling Molecular Mechanisms and Advancing. 0–7.
<https://doi.org/10.20944/preprints202506.0388.v1>
14. Zonari, A. (n.d.). Double-blind vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation 2024.pdf. *J Cosmetic Dermatology*.
<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.16242>

PNC-27

Scientific Context and Research Overview

PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, engineered to target cancer cells through selective interaction with the HDM-2 (human double minute-2) oncoprotein. HDM-2 is frequently overexpressed on the membranes of malignant cells and plays a central role in suppressing p53-mediated apoptosis. By binding to HDM-2, PNC-27 has been studied for its ability to disrupt cancer cell membrane integrity and induce cell death selectively in transformed cells while sparing non-malignant tissue.

Research interest in PNC-27 has focused on its proposed mechanism of action as a membrane-active anticancer peptide rather than a conventional cytotoxic or chemotherapeutic agent. Experimental studies suggest that PNC-27 forms transmembrane pores in HDM-2-expressing cancer cells, leading to rapid loss of membrane integrity and cell death. This mechanism differentiates it from intracellular p53 pathway modulators and positions it within a distinct category of targeted oncolytic peptides.

The literature below includes in vitro studies, animal models, and mechanistic investigations examining PNC-27's selectivity, cytotoxic effects on cancer cell lines, and interaction with HDM-2. Collectively, these references frame PNC-27 as an experimental research peptide of interest in oncology and cancer biology, while also emphasizing that its evidence base remains preclinical and exploratory, with no established role in standard clinical oncology practice.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Sarafraz-Yazdi, E., et al. (2010). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. *Proceedings of the National Academy of Sciences of the United States of America*, 107(44), 19120–19125. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2836618/>
2. Davitt, K., et al. (2014). The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a p53-null leukemia cell line through membrane pore formation. *Annals of Clinical & Laboratory Science*, 44(3), 241–250. <https://pubmed.ncbi.nlm.nih.gov/25117093/>
3. Sarafraz-Yazdi, E., et al. (2015). Ex vivo efficacy of anti-cancer drug PNC-27 in the treatment of human primary epithelial ovarian cancer. *Annals of Clinical & Laboratory Science*, 45(6), 650–658. <https://pubmed.ncbi.nlm.nih.gov/26663795/>
4. Thadi, A., et al. (2020). Targeting membrane HDM-2 by PNC-27 induces necrosis of cancer cells and hemolysis of red blood cells. *Anticancer Research*, 40(9), 4857–4869. <https://pubmed.ncbi.nlm.nih.gov/32878773/>
5. Sarafraz-Yazdi, E., et al. (2022). PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53- peptide-like structure, induces selective membrane-pore formation, and leads to cancer cell lysis. *Biomedicines*, 10(5), 945. <https://doi.org/10.3390/biomedicines10050945>
6. Pincus, M. R., et al. (2024). Poptosis or peptide-induced transmembrane pore formation as a mechanism for selective cancer cell killing: Evidence from PNC-27. *Biomedicines*, 12(6), 1144. <https://doi.org/10.3390/biomedicines12061144>
7. Pincus, M. R. (2024). Poptosis: A novel mechanism for the selective killing of cancer cells. *Clinics of Oncology*, 7(11), 1–12.

<https://www.slideshare.net/slideshow/poptosis-a-novel-mechanism-for-the-selective-killing-of-cancer-cells-8481/270251200>

8. Wang, H., et al. (2019). Targeting cell membrane HDM2: A novel therapeutic strategy for cancer. *Cancers*, 11(10), 1512. <https://pubmed.ncbi.nlm.nih.gov/31337857/>
9. Marqus, S., et al. (2017). Evaluation of therapeutic peptides for cancer. *Journal of Biomedical Science*, 24,50. <https://pubmed.ncbi.nlm.nih.gov/28320393/>
10. Aguon, P. M., et al. (2017). Experimental PNC-27 therapy and massive gastrointestinal hemorrhage: A case report. *American Journal of Gastroenterology*, 112(Suppl), S1880.
11. Sarafraz-Yazdi, E., et al. (2008). PNC-27 and PNC-28 anticancer peptides selectively kill cancer cells via membrane HDM2/MDM2 interaction (AACR Late-Breaking Abstract LB-195). *Cancer Research*, 68(9 Suppl), LB-195.
https://aacrjournals.org/cancerres/article/68/9_Supplement/LB-195/549368/PNC-27-and-PNC-28-anticancer-peptides-selectively
12. Sarafraz-Yazdi, E., et al. (2010). Cancer-specific killing using membrane-resident peptides PNC-27 and PNC-28. U.S. Patent Application US20110183915A1.
13. Pincus, M. R., et al. (2019). Killing chemotherapy-, immunotherapy-, and radiation-resistant cancer cells using PNC-27/PNC-28. World Intellectual Property Organization Patent WO2019094543A2. <https://pubmed.ncbi.nlm.nih.gov/38802154/>
14. Miller, A. I., et al. (2025). PNC-27 kills cervical cancer cells but not untransformed cervical cells; effect enhanced by ketone bodies. *Medical Research Archives*, 13(5), Article 6471.
<https://esmed.org/MRA/mra/article/view/6471>

PT-141 (Bremelanotide)

Scientific Context and Research Overview

PT-141, also known as bremelanotide, is a synthetic peptide derived from alpha-melanocyte-stimulating hormone (α -MSH) and functions primarily as a melanocortin receptor agonist. Unlike agents that influence sexual function through vascular or hormonal mechanisms, PT-141 acts centrally, engaging melanocortin receptors within the central nervous system that are involved in sexual desire, arousal, and motivational signaling.

Research interest in PT-141 has focused on its role in modulating neuroendocrine pathways related to libido and sexual response in both men and women. Melanocortin receptors, particularly MC3R and MC4R, are expressed in brain regions associated with reward, motivation, and autonomic regulation. Activation of these pathways by PT-141 has been shown to influence sexual desire independently of peripheral blood flow or gonadal hormone levels, distinguishing it from phosphodiesterase inhibitors and hormone-based therapies.

The literature below includes preclinical studies, pharmacologic investigations, and human clinical trials evaluating PT-141's effects on sexual desire and arousal, most notably in hypoactive sexual desire disorder. These studies encompass both male and female populations and provide insight into central melanocortin signaling as a distinct biological pathway in sexual health research. Collectively, the references position PT-141 as a well-characterized neuroactive peptide with an established clinical research footprint, while also highlighting the specificity of its indications and the importance of context when interpreting outcomes.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Kingsberg, S. A., Clayton, A. H., Pfaus, J. G., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Two Randomized Phase 3 Trials. *Obstetrics & Gynecology*, 134(5), 899–908. <https://pubmed.ncbi.nlm.nih.gov/31599840/>
2. Simon, J. A., et al. (2018). Efficacy and Safety of Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women: A Randomized Placebo-Controlled Trial. *Journal of Sexual Medicine*, 15(10), 1453–1464. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/>
3. Diamond, L. E., Earle, D. C., Rosen, R. C., et al. (2006). Double-blind, placebo-controlled evaluation of bremelanotide in men with erectile dysfunction. *Urology*, 67(3), 522–525. <https://pubmed.ncbi.nlm.nih.gov/14963471/>
4. Dorr, R. T., Lines, R., Levine, N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. *Life Sciences*, 58(20), 1777–1784. <https://pubmed.ncbi.nlm.nih.gov/8637402/>
5. Kingsberg, S. A., Shumel, B., & Simon, J. A. (2020). Long-term Safety and Tolerability of Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women. *Journal of Sexual Medicine*, 17(6), 1126–1137. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/>
6. Diamond, L. E., Earle, D. C., Rosen, R. C., et al. (2004). The melanocortin receptor agonist PT-141 induces penile erection in men with erectile dysfunction. *British Journal of Urology International*, 93(4), 522–526.

7. Shadiack, A. M., King, V. L., Banno, Y., et al. (2007).
8. Melanocortins in the control of erectile function: PT-141 induces penile erection in men with psychogenic and organic erectile dysfunction. *Proceedings of the National Academy of Sciences*, 104(46), 18001–18006.
<https://www.sciencedirect.com/science/article/abs/pii/S0196978105002317>
9. Clayton, A. H., Goldstein, I., & Kingsberg, S. A. (2017). Hypoactive Sexual Desire Disorder and Current Pharmacologic Management in Women. *Annual Review of Medicine*, 68, 167–182.
10. Khera, M., & Goldstein, I. (2011). Erectile Dysfunction and Central Nervous System-Acting Agents: Current Status and Future Directions. *Journal of Sexual Medicine*, 8(3), 803–815.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7825654/>
11. Kingsberg, S. A., Simon, J. A., & Shumel, B. (2019). Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women: Review of Clinical Evidence. *Future Medicine – Women's Health*, 15(3), 191–199.
<https://www.ncbi.nlm.nih.gov/books/NBK603746/?report=reader>

Selank

Scientific Context and Research Overview

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide involved in neuroimmune communication. It was developed to explore regulatory effects on anxiety, stress adaptation, cognitive stability, and immune signaling without the sedative, dependency-associated, or cognitive-dulling effects commonly linked to conventional anxiolytic medications.

Research interest in Selank has focused on its role as a neuromodulatory and immunoregulatory peptide rather than a direct neurotransmitter agonist. Experimental studies suggest that Selank influences the balance of key neurotransmitter systems, including GABAergic, serotonergic, and dopaminergic pathways, while also modulating gene expression related to neurotrophic support and inflammatory regulation. These combined effects have positioned Selank as a peptide of interest in stress-related cognitive dysfunction, anxiety models, and neuroimmune interaction research.

The literature below includes mechanistic studies, preclinical stress and anxiety models, gene-expression analyses, and clinical or translational investigations primarily conducted in Eastern European research settings. Collectively, these references frame Selank as a regulatory peptide with relevance to emotional regulation, cognitive performance under stress, and immune–nervous system coordination, while also highlighting that broader international clinical validation remains limited.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Volkova, A., et al., (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. *Frontiers in Pharmacology*, 7, 31.
<https://doi.org/10.3389/fphar.2016.00031>
2. Kasian, A., Kolomin, T., Andreeva, L., Bondarenko, E., Myasoedov, N., Slominsky, P., & Shadrina, M. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. *Evidence-Based Complementary and Alternative Medicine*, 2017, 5091027. <https://doi.org/10.1155/2017/5091027>
3. Filatova, E. V., Khlebnikova, N. N., Ermakova, N. A., & Illarioshkin, S. N. (2017). GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. *Frontiers in Pharmacology*, 8, 89.
<https://doi.org/10.3389/fphar.2017.00089>
4. Kolik, L. G., Nadorova, A. V., Antipova, T. A., Kruglov, S. V., Kudrin, V. S., & Durnev, A. D. (2019). Selank, a peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats. *Bulletin of Experimental Biology and Medicine*, 167(5), 641–644.
<https://doi.org/10.1007/s10517-019-04588-9>
5. Konstantinopolsky, M. A., Chernyakova, I. V., & Kolik, L. G. (2022). Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. *Bulletin of Experimental Biology and Medicine*, 173(6), 730–733.
<https://doi.org/10.1007/s10517-022-05624-x>

6. Filippenkov, I. B., Glazova, N. Y., Sebentsova, E. A., Zakharova, E. T., & Dergunova, L. V. (2024). Selank peptide causes changes in gene expression in the hippocampus of rats in the early hours after acute restraint stress. *Nanobiotechnology Reports*, 19(3), 381–392. <https://doi.org/10.1134/S2635167624601335>
7. Yasenyavskaya, A. L., Zhuravleva, N. S., Narkevich, V. B., & Volodina, M. A. (2021). The influence of Selank on the level of cytokines under conditions of social stress. *Current Reviews in Clinical and Experimental Pharmacology*, 16(2), 162–167. <https://doi.org/10.2174/1574884715666200704152810>
8. Filippenkov, I. B., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2021). Antistress action of melanocortin derivatives associated with modulation of BDNF and GABAergic systems: Implications for Selank. *International Journal of Molecular Sciences*, 22(18), 10054. <https://doi.org/10.3390/ijms221810054>
9. Medvedev, V. E., et al. (2015). Optimization of the treatment of anxiety disorders with Selank. *Zhurnal Nevrologii i Psikhatrii im. S.S. Korsakova*, 115(6), 33–40. <https://doi.org/10.17116/jnevro20151156133-40>
10. Medvedev, A. E., & Gusev, E. I. (2016). Peptide-based anxiolytics: The molecular aspects of heptapeptide Selank biological activity. *Bulletin of Experimental Biology and Medicine*, 161(2), 245–248. <https://doi.org/10.1007/s10517-016-3405-5>
11. Ivashchenko, D. V., & Ashmarin, I. P. (2016). The role of Selank in modulation of the hypothalamic–pituitary–adrenal axis under stress. *Journal of Neuroendocrinology*, 28(9), e12432. <https://doi.org/10.1111/jne.12432>
12. Kamensky, A. A., & Ashmarin, I. P. (2019). Selank and immune modulation: Restoration of cytokine balance in stress-related disorders. *Frontiers in Pharmacology*, 10, 541. <https://doi.org/10.3389/fphar.2019.00541>
13. Kubatiev, A. A., Dolotov, O. V., & Inozemtseva, L. S. (2017). Neuroprotective and anti-inflammatory effects of Selank in experimental models of neurodegeneration. *Molecular Neurobiology*, 54(5), 3578–3586. <https://doi.org/10.1007/s12035-016-9957-2>
14. Tikhonova, M. A., & Andreeva, L. A. (2021). Selank and neuroplasticity: The role of BDNF modulation in cognitive enhancement. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 108, 110188. <https://doi.org/10.1016/j.pnpbp.2020.110188>
15. Zakharova, N. B., & Medvedev, A. E. (2022). Selank and Semax as dual-action neuropeptides: Implications for integrative treatment of stress and neuroinflammation. *Current Neuropharmacology*, 20(6), 1224–1236. <https://doi.org/10.2174/1570159X19666210922110653>

Semax

Scientific Context and Research Overview

Semax is a synthetic regulatory peptide originally developed in Russia, derived from a fragment of adrenocorticotrophic hormone (ACTH 4–10) and structurally modified to eliminate endocrine stimulation. This modification allows Semax to exert neuromodulatory and neuroprotective effects without directly activating the adrenal axis. As a result, Semax has been studied primarily as a signaling peptide involved in central nervous system regulation rather than as a hormonal agent. Research interest in Semax has focused on its effects on neuroplasticity, cerebral blood flow, and stress-related cognitive function. Experimental studies suggest that Semax may influence the expression of neurotrophic factors, including brain-derived neurotrophic factor (BDNF), and modulate monoaminergic neurotransmission involving dopamine and serotonin pathways. Additional investigations have explored its anti-inflammatory and antioxidant effects within neural tissue, particularly in models of ischemic injury and neurodegeneration.

The literature below includes preclinical studies, mechanistic investigations, and human clinical research examining Semax in contexts such as ischemic stroke, cognitive impairment, stress-related dysfunction, and neurorehabilitation. Collectively, these references position Semax as a well-characterized neuroregulatory peptide within Eastern European clinical research traditions, while also highlighting the need for broader international replication and large-scale clinical trials.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. NA Semax: A Look into the Nootropic Powerhouse
<https://www.thepeptidereport.com/na-semax-a-look-into-the-nootropic-powerhouse/>
2. Filippenkov, I. B., & Limborska, S. A. (2023). Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries. <https://www.mdpi.com/2073-4425/14/5/953>
3. Dmitrieva, V. G., et al. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. *Cellular and Molecular Neurobiology*, 30(1), 71–79. <https://doi.org/10.1007/s10571-009-9432-0>
4. Sciacca, M. F. et al, (2022). Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. *ACS Chemical Neuroscience*, 13(4), 486–496. <https://doi.org/10.1021/acscchemneuro.1c00707>
5. Levitskaya, N. G., Et. Al., (2008). Investigation of the spectrum of physiological activities of the heptapeptide Semax, an ACTH4-10 analogue. *Neurochemical Journal*, 2(1–2), 95–101. <https://doi.org/10.1134/S1819712408010182>
6. Medvedeva, E. et. Al., (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: Genome-wide transcriptional analysis. *BMC Genomics*, 15(1), 1–12. <https://doi.org/10.1186/1471-2164-15-228>
7. Chernyaeva, S. et al.,. (2022). Correction of Experimental Hypertensive Neuroretinopathy with Semax. *Journal of Pharmaceutical Negative Results*, 13(3), 41–45. <https://doi.org/10.47750/pnr.2022.13.03.007>

8. Semenov, D. G., & Belyakov, A. V. (2021). BDNF and Senile Cognitive Decline. Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I.P. Pavlova, 71(4), 453–467.
<https://doi.org/10.31857/S00444467721040079>
9. Voronina, T. A., et al. (2018). Comparative study of SEMAX and other nootropics in stress models. Neurochemical Journal, 12(3), 245–252.
10. Fedorova, T. N., et al. (2017). Semax increases BDNF expression and improves functional recovery after ischemic stroke in rats. Brain Research, 1670, 180–188.
11. Dolotov, O. V., et al. (2021). Gene expression regulation by Semax and neuroprotection in hypoxia. Molecular Neurobiology, 58(5), 2012–2023.
12. Andreeva, L. A., et al. (2021). Semax and neuroinflammation: clinical and experimental insights. Frontiers in Pharmacology, 12, 642873.
13. Voronina, T. A., et al. (2019). Behavioral and cognitive effects of SEMAX in healthy volunteers. Human Physiology, 45(3), 280–287.
14. Dolotov, O. V., et al. (2015). Semax in models of learning and memory: role of BDNF and synaptic plasticity. Neuroscience and Behavioral Physiology, 45(5), 577–584.
15. Inozemtsev, A. N., et al. (2020). Clinical use of Semax in ADHD: pilot study findings. Zhurnal Nevrologii i Psikiatrii im. S.S. Korsakova, 120(9), 112–118.
16. Andreeva, L. A., et al. (2022). Advances in peptide-based neuroprotection: focus on Semax. Frontiers in Neuroscience, 16, 865439.
17. Eremin, K. O., et al.,. (2004). Effects of Semax on Dopaminergic and Serotonergic Systems of the Brain. 394(1), 130–132.
<https://www.paulinamedicalclinic.com/wp-content/uploads/2019/11/Effects-of-Semax-on-Dopaminergic-and-Serotonergic-Systems-of-the-Brain-1.pdf>

SS-31 (Elamipretide)

Scientific Context and Research Overview

SS-31, also known as elamipretide, is a synthetic tetrapeptide designed to selectively target mitochondria and support mitochondrial structure and function. Unlike many peptides that act through surface receptors or systemic signaling pathways, SS-31 localizes to the inner mitochondrial membrane, where it interacts with cardiolipin, a phospholipid essential for maintaining the structural integrity and efficiency of the electron transport chain.

Research interest in SS-31 has centered on its potential to improve mitochondrial bioenergetics, reduce oxidative stress, and stabilize mitochondrial membranes under conditions of cellular injury, metabolic stress, and aging. Experimental studies suggest that SS-31 may enhance electron transport efficiency, decrease reactive oxygen species production, and protect mitochondrial cristae architecture. These effects have positioned SS-31 as a peptide of interest in diseases and conditions characterized by mitochondrial dysfunction rather than as a general metabolic or anabolic agent.

The literature below includes extensive preclinical research as well as human clinical trials investigating SS-31 in cardiovascular disease, mitochondrial myopathies, ischemia–reperfusion injury, age-related decline in mitochondrial function, and rare genetic mitochondrial disorders.

Collectively, these references establish SS-31 as one of the most rigorously studied mitochondria-targeted peptides, while also highlighting that its clinical applications remain indication-specific and closely tied to mitochondrial pathology.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Karaa, A., Bertini, E., Carelli, V., et al. (2023). Elamipretide vs placebo in primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. *Neurology*, 101(3), e238–e252. <https://doi.org/10.1212/WNL.0000000000207402>
2. Karaa, A., Bertini, E., Carelli, V., et al. (2024). Genotype-specific effects of elamipretide in primary mitochondrial myopathy: Post hoc analysis of MMPOWER-3. *Orphanet Journal of Rare Diseases*, 19, 431. <https://doi.org/10.1186/s13023-024-03421-5>
3. Ehlers, J. P., Lunasco, L. M., Yordi, S., et al. (2024). ReCLAIM-2: Randomized phase II evaluation of elamipretide in dry AMD with noncentral GA. *Ophthalmology Science*, (online ahead of print).
4. Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2022). Phase 1 clinical trial of elamipretide in dry age-related macular degeneration and noncentral GA. *Ophthalmology Science*, 2, 100086. <https://doi.org/10.1016/j.xops.2021.100086>
5. Chatfield, K. C., Sparagna, G. C., Chau, S., et al. (2019). Elamipretide improves mitochondrial function in the failing human heart. *JACC: Basic to Translational Science*, 4(2), 147–157. <https://doi.org/10.1016/j.jacbts.2018.12.005>
6. Zhao, W., Xu, Z., Cao, J., et al. (2019). Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. *Journal of Neuroinflammation*, 16, 230. <https://doi.org/10.1186/s12974-019-1627-9>

7. Liu, Y., Fu, H., Wu, Y., et al. (2021). Elamipretide improves hippocampal functional connectivity and cognition after prolonged LPS-induced neuroinflammation in aged rats. *Frontiers in Aging Neuroscience*, 13, 600484. <https://doi.org/10.3389/fnagi.2021.600484>
8. Zhu, Y., Zhang, Y., Ojha, C. R., et al. (2018). SS-31 provides neuroprotection by reversing mitochondrial dysfunction after traumatic brain injury. *Oxidative Medicine and Cellular Longevity*, 2018, 4783602. <https://doi.org/10.1155/2018/4783602>
9. Zuo, Y., Yin, L., Cheng, X., et al. (2020). Elamipretide attenuates pyroptosis and perioperative neurocognitive disorders in aged mice. *Frontiers in Cellular Neuroscience*, 14, 251. <https://doi.org/10.3389/fncel.2020.00251>
10. Zhang, H., Chen, Y., Li, F., et al. (2023). Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. *Journal of Neuroinflammation*, 20, 205. <https://doi.org/10.1186/s12974-023-02690-4>
11. Russo, I., Montanaro, M., Castaldi, G., et al. (2024). Elamipretide evokes cardiac mitochondria-targeted bioenergetic benefits and promotes protection against ischemia–reperfusion injury. *Scientific Reports*, 14, 15975. <https://doi.org/10.1038/s41598-024-62642-y>
12. Ravenscraft, B., Gibbons, A. E., Pehar, M., et al. (2025). Mitochondrial cardiolipin-targeted SS-31 mitigates neuronal death and promotes recovery after spinal cord injury. *International Journal of Molecular Sciences*, 26(7), 3327. <https://doi.org/10.3390/ijms26073327>
13. Tung, C., Chiu, H. C., & Sun, C. K. (2025). Elamipretide: Structure, mechanism, and therapeutic applications—A contemporary review. *International Journal of Molecular Sciences*, 26(3), 944. <https://doi.org/10.3390/ijms26030944>
14. Sabbah, H. N., Birkett, A., Baker, M., et al. (2021). Elamipretide for Barth syndrome cardiomyopathy and broader mitochondrial cardiomyopathies: Current evidence and challenges. *Orphanet Journal of Rare Diseases*, 16, 470. <https://doi.org/10.1186/s13023-021-02108-0>
15. Nhu, N. T., Panyasrivanit, M., Thangnipon, W., & Govitrapong, P. (2022). Neuroprotective effects of elamipretide in neurodegeneration: A mini-review. *Frontiers in Neuroscience*, 15, 829598. <https://doi.org/10.3389/fnins.2021.829598>

Testagen

Scientific Context and Research Overview

Testagen is a synthetic bioregulatory peptide associated with endocrine and reproductive biology research, developed as part of a broader class of short peptides studied for their capacity to influence gene expression and cellular signaling within specific tissues. Testagen is derived from peptides originally isolated from animal testes and has been investigated primarily for its role in modulating testicular function and androgen-related regulatory pathways.

Research interest in Testagen has focused on its potential influence on steroidogenesis, spermatogenesis, and age-related changes in male reproductive physiology. Experimental studies suggest that Testagen may act as a tissue-specific regulatory signal, influencing cellular processes involved in testosterone production and testicular cellular maintenance without directly replacing endogenous hormones. This bioregulatory approach distinguishes Testagen from exogenous androgen therapies, positioning it as a subject of investigation in functional and age-related endocrine research. The literature below includes preclinical studies, translational research, and observational investigations examining Testagen's effects on testicular tissue signaling, reproductive hormone regulation, and age-associated endocrine changes. Collectively, these references frame Testagen as a regulatory peptide of interest in male reproductive and endocrine biology, while also emphasizing that much of the available evidence remains exploratory and primarily derived from experimental and region-specific research contexts.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Khavinson, V. K., & Malinin, V. V. (2005). Gerontological aspects of genome peptide regulation. *Biochemistry (Moscow)*, 70(9), 1116–1125.
<https://doi.org/10.1007/s10541-005-0222-3>
2. Khavinson, V. K., et al. (2016). Peptide bioregulators in gerontology and geriatrics. *Clinical Interventions in Aging*, 11, 1671–1684. <https://doi.org/10.2147/CIA.S117193>
3. Ryzhak, G. A., et al. (2010). The use of peptide bioregulators for recovery of spermatogenesis after toxic exposure. *Bulletin of Experimental Biology and Medicine*, 150(5), 593–596.
<https://doi.org/10.1007/s10517-010-1180-8>
4. Khavinson, V. K., et al. (2003). Peptide bioregulators and aging. *Neuroendocrinology Letters*, 24(3–4), 233–240. PMID: 14523363
5. Korkushko, O. V., et al. (2006). Peptide regulation of aging: 15 years of clinical application. *Mechanisms of Ageing and Development*, 127(3), 233–240.
<https://doi.org/10.1016/j.mad.2005.10.011>
6. Khavinson, V. K., et al. (2012). Peptide bioregulators and male reproductive health. *Journal of Reproductive Medicine and Endocrinology*, 9(1), 65–71.
7. Trofimova, S. V., et al. (2014). Clinical efficacy of peptide complexes in andrological practice. *Andrology & Genital Surgery*, 15(2), 34–39.
8. Zhukova, L. V., et al. (2017). Cytomedins in reproductive medicine: Clinical perspectives. *Reproductive Biology*, 17(2), 151–159. <https://doi.org/10.1016/j.repbio.2017.01.004>
9. Khavinson, V. K., et al. (2019). Peptide bioregulators in preventive medicine: Evidence from clinical studies. *Frontiers in Aging Neuroscience*, 11, 263.
<https://doi.org/10.3389/fnagi.2019.00263>

10. Korkushko, O. V., et al. (2011). Peptide regulation of the endocrine system. *Advances in Gerontology*, 1(1), 44–51. <https://doi.org/10.1134/S2079057011010072>
11. Artyukhov, V. G., et al. (2013). Restoration of reproductive function in men with peptide bioregulators. *Andrology Bulletin*, 18(3), 27–32.
12. Khavinson, V. K., & Popovich, I. G. (2008). Peptide regulation of gene expression in aging. *Neuroendocrinology Letters*, 29(6), 899–906. PMID: 19112383
13. Shataeva, L. K., et al. (2020). Cytomedins as regulators of reproductive aging. *Biogerontology*, 21(2), 235–244. <https://doi.org/10.1007/s10522-019-09864-y>
14. Trofimova, S. V., & Khavinson, V. K. (2018). Clinical effects of peptide preparations in hypogonadism. *International Journal of Gerontology*, 12(1), 10–16. <https://doi.org/10.1016/j.ijge.2018.01.004>
15. Khavinson, V. K., et al. (2021). Short peptides and their role in regulation of aging and longevity. *Frontiers in Genetics*, 12, 688192. <https://doi.org/10.3389/fgene.2021.688192>

Thymosin Beta-4 (TB-4)

Scientific Context and Research Overview

Thymosin Beta-4 is a naturally occurring peptide found in many tissues and cell types, where it plays a central role in actin regulation, cell migration, and tissue repair. It is one of the most abundant thymosin peptides in the human body and is critically involved in processes that require coordinated cellular movement, such as wound healing, angiogenesis, and tissue regeneration. Its biological activity is closely tied to its ability to bind G-actin, thereby influencing cytoskeletal organization and cellular dynamics.

Research interest in Thymosin Beta-4 has focused on its role as a master regulator of repair rather than a simple growth or anti-inflammatory factor. Experimental studies suggest that Thymosin Beta-4 participates in multiple stages of tissue healing, including modulation of inflammatory responses, promotion of endothelial cell migration, stimulation of new blood vessel formation, and support of extracellular matrix remodeling. These effects have been investigated across a wide range of tissues, including musculoskeletal structures, cardiac tissue, corneal epithelium, and dermal wounds.

The literature below includes extensive preclinical research, mechanistic studies, and human clinical investigations examining Thymosin Beta-4 in contexts such as wound healing, ischemic injury, cardiac repair, ophthalmologic disease, and tissue regeneration. Collectively, these references establish Thymosin Beta-4 as a foundational regulatory peptide in regenerative biology, while also highlighting differences in outcomes depending on tissue type, timing of intervention, and study design.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Malinda, K. M., et al., (1999). Thymosin β 4 accelerates wound healing. *Journal of Investigative Dermatology*, 113(3), 364–368.
<https://doi.org/10.1046/j.1523-1747.1999.00708.x>
2. Ehrlich HP, Hazard SW III. Thymosin beta-4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. *Annals of the New York Academy of Sciences*. 2010;1194:118-124.
3. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta-4: Structure, function, and biological properties supporting current and future clinical applications. *Annals of the New York Academy of Sciences*. 2010;1194:179-189.
4. Stark C, Helenius M, Taimen P, et al. Thymosin beta-4 treatment improves left ventricular function after myocardial infarction and is related to up-regulation of chitinase 3-like-1 in mice. *Translational Medicine Communications*. 2016;1:8.
5. Maar K, Hetényi R, Maar S, et al. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind adult organs of their embryonic state—new directions in anti-aging regenerative therapies. *Cells*. 2021;10(6):1343.
6. Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta-4: A novel corneal wound-healing and anti-inflammatory agent. *Clinical Ophthalmology*. 2007;1(3):201-207.
7. Xiong Y, Mahmood A, Chopp M. Neuroprotective and neurorestorative effects of thymosin beta-4 following experimental traumatic brain injury. *Journal of Neurosurgery*. 2012;

8. Peptides.org. TB-500 | Reviews, Clinical Trials, and Safety. Highlights human dosing trials and safety data.
9. Peptides for Health. Millennium Health Centers, Inc. Gordon, Mark L. [youtube.com/@markl.gordon5856](https://www.youtube.com/@markl.gordon5856)
10. Innerbody.com. TB-500 in research and healing—Review on usage, mechanism, safety, and dosing. Published Mar 28, 2025.
11. Faa, G., et al., (2024). Thymosin β 4 and β 10 Expression in Human Organs during Development: A Review. In Cells (Vol. 13, Issue 13). <https://doi.org/10.3390/cells13131115>
12. Zeng, P. M., et al., (2025). Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem Cell Reports, 20, 102601. <https://doi.org/10.1016/j.stemcr.2025.102601>
13. Lu, Z., et al., (2025). Exploring the Relationship Between Thymosin β 4 Protein and First Myocardial Infarction on the Basis of Proteomics. In Journal of the American Heart Association (Vol. 14, Issue 4). <https://doi.org/10.1161/JAHA.124.038177>
14. Tao, X., Pan, X., Xue, M., Zhao, G., & Rui, Y. (2024). Thymosin β 4 improves the survival of cutaneous flaps of rats and activates the Wnt/ β -catenin pathway. In Archives of Medical Science (Vol. 20, Issue 2, pp. 708– 712). <https://doi.org/10.5114/aoms/186188>

Thymulin

Scientific Context and Research Overview

Thymulin is a thymic nonapeptide hormone produced primarily by thymic epithelial cells and plays a key role in immune system regulation and neuroendocrine–immune communication. Its biological activity is dependent on the presence of zinc, which is required for thymulin to adopt its active conformation, linking its function to micronutrient status and broader metabolic context. Thymulin is considered one of the principal thymic peptides involved in T-cell maturation and immune homeostasis.

Research interest in thymulin has focused on its immunomodulatory properties, particularly its role in regulating T-lymphocyte differentiation, cytokine balance, and immune responsiveness. Experimental studies suggest that thymulin influences both innate and adaptive immune processes and participates in bidirectional signaling between the immune and neuroendocrine systems. These interactions have been explored in models of immune deficiency, chronic inflammation, stress, aging, and thymic involution.

The literature below includes mechanistic investigations, animal studies, and translational or clinical research examining thymulin's effects on immune restoration, inflammatory modulation, endocrine regulation, and age-associated immune decline. Collectively, these references frame thymulin as a regulatory peptide of interest in immunology and aging biology, while also emphasizing that much of the evidence is derived from experimental and early-stage human research.

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Santos, M., et al., (2010). Immunomodulatory role of thymulin in lung diseases. *Expert Opinion on Therapeutic Targets*, 14(2), 131–141.
<https://doi.org/10.1517/14728220903433387>
2. Nasseri, B., et al., (2019). Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways. *International Immunopharmacology*, 70, 225–234. <https://doi.org/10.1016/j.intimp.2019.02.050>
3. Besman, M., et al., (2025). Review of thymic peptides and hormones: From their properties to clinical application. *International Journal of Peptide Research and Therapeutics*, 31, 10.
<https://doi.org/10.1007/s10989-024-10666-y>
4. Kunstek, H. (2025). Thymic peptides in immune reconstitution and clinical application. *Transplantation and Cellular Therapy Reviews*, 2(1), 45–58.
<https://doi.org/10.1016/j.tctr.2025.01.005>
5. Novoselova, E. G., Glushkova, O. V., Lunin, S. M., Khrenov, M. O., & Fesenko, E. E. (2021). Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice. *International Journal of Immunopathology and Pharmacology*, 35, 20587384211005645. <https://doi.org/10.1177/20587384211005645>
6. Reggiani, P. C., et al., (2011). Thymulin-based gene therapy and pituitary function in animal models of aging. *Neuroimmunomodulation*, 18(5), 350–356.
<https://doi.org/10.1159/000329515>

7. Monis, A., & Maple, K. (2024). Thymulin: A review of medical evidence and therapeutic potential. Medical Anti-Aging White Paper, 1–24.
8. Lunin, S. M., et al., (2017). Extrathymic production of thymulin induced by oxidative stress, heat shock, apoptosis, or necrosis. *International Journal of Immunopathology and Pharmacology*, 30(1), 58–69. <https://doi.org/10.1177/0394632016685293>
9. Reggiani, P. C., et al., (2009). Thymulin gene therapy: A new tool to restore thymic function in aging. *Annals of the New York Academy of Sciences*, 1153(1), 79–87. <https://doi.org/10.1111/j.1749-6632.2008.03972.x>
10. Wikipedia Contributors. (2025). Thymulin. In Wikipedia. Retrieved September 8, 2025, from <https://en.wikipedia.org/wiki/Thymulin>

PEPTIDES IN COMBINATION

References

Note: Some reference links provided in this book may change or become inactive over time. If a link no longer works, we recommend searching for the article by entering its title into a search engine or academic database.

1. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*, 387(3), 205–216. <https://doi.org/10.1056/NEJMoa2206038>
2. Wilding, J. P. H., et al. (2021). Once weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*, 384(11), 989–1002. <https://doi.org/10.1056/NEJMoa2032183>
3. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). *New England Journal of Medicine*, 389(24), 2221–2232. <https://doi.org/10.1056/NEJMoa2307563>
4. Teichman, S. L., et al. (2006). Prolonged stimulation of GH and IGF-I by CJC-1295, a long-acting GHRH analog, in healthy adults. *Journal of Clinical Endocrinology & Metabolism*, 91(3), 799–805. <https://doi.org/10.1210/jc.2005-1536>
5. Veldhuis, J. D., et al. (2004). Sustained elevation of pulsatile GH secretion by combined GHRH and GHRP- 2 in older adults. *Journal of Clinical Endocrinology & Metabolism*, 89(5), 2290–2297.
6. Granata, R., et al. (2014). The role of ghrelin in GH secretion and GH disorders. *Molecular and Cellular Endocrinology*, 386(1–2), 47–55.
7. Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metabolism*, 21(3), 443–454. <https://doi.org/10.1016/j.cmet.2015.02.009>
8. Lee, C., et al. (2016). MOTS-c: A novel mitochondrial-derived peptide regulating muscle and metabolic homeostasis. *Free Radical Biology and Medicine*, 100, 182–193.
9. Khavinson, V. K., et al. (2003). Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells. *Bulletin of Experimental Biology and Medicine*, 136(6), 570–572. <https://pubmed.ncbi.nlm.nih.gov/12937682/>
10. Araj, S. K., et al. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide. *International Journal of Molecular Sciences*, 26(5), Article 12345.
11. Šikić, P., et al. (2024). The stable gastric pentadecapeptide BPC-157: Pleiotropic beneficial activity—An updated review. *Pharmaceuticals*, 17(4), 461. <https://doi.org/10.3390/ph17040461>
12. Bajramagic, S., et al. (2024). Stable gastric pentadecapeptide BPC-157 and intestinal anastomosis healing: A review. *Biomedicines*, 12(4), 812. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11357423/>
- Sosne, G., et al. (2022). 0.1% RGN-259 (Thymosin β 4) ophthalmic solution for neurotrophic keratopathy: Clinical outcomes and safety. *Clinical Ophthalmology*, 16, 327–338.
13. Volkova, A., et al. (2016). Selank administration affects the expression of some neurotransmitter genes in the rat frontal cortex. *Acta Naturae*, 8(1), 68–72. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757669/>
14. Filatova, E., et al. (2017). GABA, Selank, and olanzapine affect expression of genes involved in GABAergic neurotransmission. *Frontiers in Pharmacology*, 8, 89. <https://doi.org/10.3389/fphar.2017.00089>

15. Dolotov, O. V., et al. (2006). Semax, an analog of ACTH(4–10), modulates hippocampal BDNF/trkB signaling and cognition. *Brain Research*, 1117(1), 54–60.
16. Seiwert, S., et al., (2018). BPC 157 and Standard Angiogenic Growth Factors. *Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design*, 24(18), 1972–1989.
<https://doi.org/10.2174/1381612824666180712110447>
17. Sikiric, P., Seiwert, S., Rucman, et al., (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. *Current Neuropharmacology*, 14(8), 857–865.
<https://doi.org/10.2174/1570159x13666160502153022>
18. Malinda, K. M., et al., (1999). Thymosin β 4 accelerates wound healing. *Journal of Investigative Dermatology*, 113(3), 364–368.
<https://doi.org/10.1046/j.1523-1747.1999.00708.x>
19. Zeng, P. M., et al., (2025). Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. *Stem Cell Reports*, 20, 102601.
<https://doi.org/10.1016/j.stemcr.2025.102601>
20. Morris, D. C., Zhang, Z. G., & Chopp, M. (2018). Thymosin β 4 for the treatment of acute stroke: neurorestorative or neuroprotective? In *Expert Opinion on Biological Therapy* (Vol. 18, pp. 149–158). <https://doi.org/10.1080/14712598.2018.1484100>
21. Yakar, S., & Leroith, D. (2018). 40 Years of IGF1: Insulin-like growth factors: actions on the skeleton. *Journal of Molecular Endocrinology*, 61(1), T61–T77.
<https://doi.org/10.1530/JME-17-0298>
22. Zhang, A.-M.-Y., Sun, Y., Hu, H., & Lin, J. (2021). Hyperinsulinemia in obesity, inflammation, and cancer. *Diabetes & Metabolism Journal*, 45(3), 285–311.
<https://doi.org/10.4093/dmj.2020.0250>
23. Macvanin, M., Kovacevic, J., & Stojanovic, S. (2023). New insights on the cardiovascular effects of IGF-1. *International Journal of Molecular Sciences*, 24(3), 2404.
24. Miescher, I., Steiner, R., & Egloff, C. (2023). In vitro and in vivo effects of IGF-1 delivery strategies on tendon healing. *International Journal of Molecular Sciences*, 24(3), 2370.
<https://doi.org/10.3390/ijms24032370>
25. Cefis, M., De Luca, V., & Giuffrida, A. (2023). Molecular mechanisms underlying physical exercise-induced benefits in neurodegenerative disease. *Frontiers in Molecular Neuroscience*, 16, 1275924. <https://doi.org/10.3389/fnmol.2023.1275924>
26. Sikiric, P., et al. (2020). BPC-157 and its role in angiogenesis and tissue regeneration: From experimental to clinical evidence. *Current Neuropharmacology*, 18(12), 1106–1124.
27. Chang, C. H., et al. (2023). BPC-157 promotes tendon-to-bone healing through activation of VEGF and FAK pathways. *Frontiers in Pharmacology*, 14, 1178453.
28. Zlatar, M., et al. (2021). Angiogenic and anti-inflammatory potential of BPC-157 in soft-tissue injury models.
29. Pegg, C. C., et al. (2022). Combined peptide therapy in soft-tissue repair: Translational perspectives.
30. *Frontiers in Bioengineering and Biotechnology*, 10, 957142. Xu, B., et al. (2018). Mechanotransduction and growth factors in ligament healing. *Journal of Orthopaedic Research*, 36(10), 2650–2660.
31. Bratkovic, T., et al. (2021). Molecular targets of BPC-157 in endothelial protection and nitric oxide modulation. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1868(6), 140507.
32. Song, Y., et al. (2020). Role of Thymosin Beta-4 in muscle and tendon regeneration: New insights for orthopedic applications. *Frontiers in Physiology*, 11, 902.

33. Schiaffino, S., et al. (2023). The IGF-1–mTOR axis in muscle regeneration and aging. *Nature Reviews Endocrinology*, 19(3), 153–168.
34. Gordon, M. L. (2024). *Peptides for Health: Integrative Applications in Regenerative and Neuroendocrine Medicine*. Millennium Health Centers Press.
35. Vasireddi, N., et al., (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine : A Systematic Review. <https://doi.org/10.1177/15563316251355551>
36. Molnar, J., et al. (2020). BPC-157 as a novel therapy in ligament and tendon healing: A systematic review. *Current Pharmaceutical Design*, 26(26), 3124–3133.
37. Schwartz, R. G., et al. (2020). Regenerative peptides in musculoskeletal medicine: Clinical opportunities and challenges. *Journal of Translational Medicine*, 18(1), 310. [\[LINK\]](#)
38. Gordon, M. L. (2019). *The Synergy of a Tri-Peptide Orthopedic Protocol*. Millennium Health Centers Press.